

---

**Kenya**  
**Essential**  
**Medicines**  
**List 2016**



## Additions

| #       | Item Added   | Indication/Notes  |
|---------|--|---|
| 1.1.1.2 | Isoflurane   | Inhalational anaesthesia; improved adverse effect profile; replaced halothane in some countries                         |
| 1.1.1.3 | Medical air inhalation (medicinal gas)                       | Useful substitute for nitrous oxide in patients sensitive to oxygen toxicity  |
| 1.1.2.2 | Propofol injection 10mg/mL                                   | IV anaesthesia (alt: thiopentone); improved adverse effect profile, more rapid recovery; useful for diagnostic sedation |
| 1.2.2   | a) LidocaineHCl injection 2% (30mL vial) (preservative-free) | Replaces lignocaine HCl injection 1% (can be diluted to make 1% as required)  |
|         | b) LidocaineHCl topical solution 2% (spray bottle)           | Replaces lignocaine topical solution 4%   |
| 1.3.2   | Chlorphenamine maleate injection 10mg/1mL amp                | Allergic reactions to morphine  |
| 1.3.5   | <i>Fentanyl injection 50 micrograms/mL</i>                   | <i>Useful intraoperative medication (rapid onset, short-acting)</i>   |
| 1.3.3   | a) Midazolam injection 1mg/1mL amp                           | Replace diazepam presentations (faster onset and recovery)  |
|         | b) Midazolam oral liquid 2mg/mL [c]                          |   |
|         | c) Midazolam tablet 7.5mg                                    |   |
| 2.1.3   | a) Paracetamol injection 10mg/mL (100mL vial)                | Post-operative analgesia <b>only</b>  |
| 2.2.2   | b) Morphine oral liquid 1mg/mL                               | Severe chronic pain   |
|         | c) Morphine oral liquid 10mg/mL                              |   |
|         | d) Morphine tablet 30mg (prolonged-release)                  | Replaces 60mg (for greater dosing flexibility)  |
| 2.3.4   | c) Diazepam gel or rectal solution 5mg/mL (0.5mL tube)       | Alternative presentation (where oral route not possible)  |
| 2.3.5   | Gabapentin tablet 300mg                                      | Neuropathic pain  |
| 2.3.6   | a) Haloperidol injection 5mg/1mL amp                         | Improved symptom management in palliative care  |
|         | b) Haloperidol tablet 5mg                                    |   |
| 2.3.7   | Hyoscine butylbromide injection 20mg/mL                      |   |
| 2.3.9   | Lactulose oral liquid 3.1-3.7mg/5mL [c]                      |   |
| 2.3.11  | Loperamide tablet 2mg  |   |
| 2.3.12  | a) Metoclopramide injection 5mg/mL                           |   |
|         | b) Metoclopramide oral liquid 5mg/5mL                        |   |
|         | c) Metoclopramide tablet 10mg                                |   |
| 2.3.13  | c) Midazolam oral liquid 2mg/mL [c]                          |   |
|         | d) Midazolam tablet 7.5mg                                    |   |

## KEML 2016

| #       | Item Added   | Indication/Notes   |
|---------|--|--|
| 2.3.14  | a) Ondansetron injection 2mg/mL [c]<br>b) Ondansetron tablet 4mg [c]   |  |
| 3.1     | a) Cetirizine oral liquid 5mg/5mL<br>b) Cetirizine tablet 10mg   | Replaces deleted chlorphenamine (better adverse effect profile)  |
| 4.1.1   | Activated charcoal PFOL 50g  | Replaces activated charcoal tablet 250mg as preferred presentation                                       |
| 4.2.3   | a) Deferasirox tablet 100mg<br>b) Deferasirox tablet 400mg   | Iron poisoning   |
| 4.2.4   | Flumazenil injection 100mcg/mL   | Benzodiazepine poisoning   |
| 4.2.6   | Protamine sulphate injection 10mg/mL   | Heparin overdose   |
| 4.2.9   | a) Ethanol injection 100%<br>b) Ethanol oral liquid 95-96%   | Methanol poisoning   |
| 4.2.10  | Fomepizole sulphate injection 5mg/mL   | Methanol poisoning   |
| 4.2.12  | Pralidoxime chloride PFI 1g  | Organophosphate poisoning  |
| 4.2.14  | Sodium nitrite injection 30mg/mL   |  |
| 4.2.15  | Sodium thiosulphate injection 250mg/mL   | Cyanide poisoning  |
| 5.2     | Diazepam gel or rectal solution 5mg/mL   | Replaces diazepam injection in children (preferable presentation)  |
| 5.3     | Gabapentin tablet 300mg  | Focal seizures   |
| 5.4     | Lorazepam injection 4mg/mL   | Replaces diazepam injection in adults (recommended 1 <sup>st</sup> line, better adverse effects profile) |
| 5.6     | a) Phenobarbital sodium injection 30mg/1mL amp [c]   | Paediatric emergencies   |
| 5.9     | a) Lamotrigine tablet 25mg   |  |
| 5.9     | b) Lamotrigine tablet 100mg  | Refractory epilepsy  |
| 6.1.2.1 | Albendazole tablet 400mg (chewable)  |  |
| 6.1.2.2 | Diethylcarbamazine tablet 100mg (scored)   | Required for current management protocols  |
| 6.2.1.1 | a) Amoxicillin tablet 250mg (dispersible, scored)  | Replaces PFOL 125mg/5mL  |
| 6.2.1.2 | a) Amoxicillin + clavulanic acid tablet 200mg + 28.5mg (DT, scored)<br>b) Amoxicillin + clavulanic acid tablet 875mg + 125mg | Replaces PFOL 250mg + 62.5mg/5mL<br>Replaces tablet 625mg  |
| 6.2.1.3 | Benzathine penicillin PFI 900mg (1.2MU) vial   | Preferred presentation; replaces 1.44g (2.4MU) vial  |
| 6.2.1.5 | Cefazolin PFI 1g vial  | For restricted use in surgical premedication   |

## KEML 2016

| #         | Item Added   | Indication/Notes   |
|-----------|--|--|
|           |  | prophylaxis  |
| 6.2.1.9   | Phenoxyethylpenicillin tablet 250mg  | For restricted use in sickle-cell prophylaxis & rheumatic heart disease prophylaxis (as alternative to benzathine penicillin where this is unsuitable) |
| 6.2.1.11  | a) Imipenem + cilastin PFI 250mg + 250mg vial                                | For specialist 2nd line use <b>only</b> in life-threatening hospital-acquired infections due to suspected or proven multi-drug resistant organisms     |
|           | b) Imipenem + cilastin PFI 500mg + 500mg vial                                |  |
| 6.2.2.2   | a) Ciprofloxacin oral liquid 250mg/5mL [c]                                   | For use in children  |
| 6.2.2.9   | Tinidazole tablet 500mg  | Alternative to metronidazole; longer action permits single daily dosing for improved adherence   |
| 6.2.2.10  | Ciprofloxacin solution for IV infusion 2mg/mL (50mL bottle) (as lactate) [c] | Required additional dose form for use in children  |
| 6.2.3.1   | a) Clofazamine capsule 50mg  | For use in recommended national treatment regime   |
|           | b) Clofazamine capsule 100mg   |  |
| 6.2.4.9   | b) Rifampicin + isoniazid + pyrazinamide + (RHZ) [c] 75mg + 50mg + 150mg     | Required paediatric dose-form  |
| 6.2.4.12  | Bedaquiline tablet 100mg   | For specialist use in MDR TB   |
| 6.2.4.13  | Capreomycin PFI 1g vial  |  |
| 6.2.4.14  | Cycloserine tablet 250mg   |  |
| 6.2.4.15  | Delamanid tablet 50mg  |  |
| 6.2.4.17  | Levofloxacin tablet 500mg (scored)   |  |
| 6.2.4.18  | Linezolid tablet 600mg   |  |
| 6.2.4.19  | Moxifloxacin tablet 400mg  |  |
| 6.2.4.20  | p-aminosalicylic acid granules 4g  |  |
| 6.2.4.21  | Prothionamide tablet 250mg   |  |
| 6.2.4.22  | Rifabutin capsule 150mg  |  |
| 6.3.1     | Clotrimazole vaginal tablet 500mg  | Replaces 200mg (improved adherence)  |
| 6.4.1.1   | Aciclovir PFI 250mg vial   | Required additional presentation   |
| 6.4.2.2.1 | a) Efavirenz tablet 200mg  | Required for updated HIV management regimes  |
|           | b) Efavirenz tablet 600mg  |  |
| 6.4.2.2.2 | Etravirine tablet 100mg  |  |
| 6.4.2.3.1 | Atazanavir + ritonavir tablet 300mg + 100mg                                  |  |
| 6.4.2.3.2 | Darunavir tablet 600mg (f/c)   |  |
| 6.4.2.3.4 | Ritonavir oral liquid 400mg/5mL  |  |
| 6.4.2.4.1 | Raltegravir tablet 25mg (chewable)   |  |

## KEML 2016

| #         | Item Added   | Indication/Notes  |
|-----------|--|---|
|           | Raltegravir tablet 100mg (chewable)  |   |
|           | Raltegravir tablet 400mg (f/c)   |   |
| 6.4.2.5.1 | Abacavir + lamivudine tablet (dispersible) 60mg + 30mg   |   |
| 6.4.2.5.2 | Efavirenz + lamivudine + tenofovir tablet 600mg + 300mg + 300mg  |   |
| 6.4.2.5.3 | Lamivudine + tenofovir tablet 300mg + 300mg  |   |
| 6.4.2.5.4 | a) Lamivudine + zidovudine tablet 30mg + 60mg  |   |
| 6.4.3.1   | Ganciclovir PFI 500mg vial   | Cytomegalovirus retinitis (CMV)   |
| 6.4.3.2   | a) Ribavirin tablet 200mg (film coated)<br>b) Ribavirin tablet 400mg (film coated)   | Viral haemorrhagic fevers and hepatitis C   |
| 6.4.4.1.1 | Pegylated interferon alfa-2a injection 180 micrograms (vial or prefilled syringe)  | Hepatitis B   |
| 6.4.4.1.2 | Tenofovir disoproxil fumarate tablet 300mg   |   |
| 6.4.4.2.1 | Pegylated interferon alfa-2a injection 180 micrograms (vial or prefilled syringe)  | Hepatitis C   |
| 6.4.4.2.2 | a) Ribavirin tablet 200mg (f/c)<br>b) Ribavirin tablet 400mg (f/c)   |   |
| 6.5.3.1.1 | b) Artemether + lumefantrine tablet 20mg + 120mg (dispersible)<br>c) Artemether + lumefantrine tablet 80mg + 480mg                 | For patients <24kg<br>For patients >35kg; reduced pill burden                           |
| 6.5.3.1.2 | a) Artesunate injection 30mg vial<br>b) Artesunate injection 60mg vial   | Reduced waste in paediatric use<br>For 1 <sup>st</sup> line treatment of severe malaria |
| 6.5.3.2.2 | Proguanil HCl tablet 100mg   | For malaria prophylaxis in sicklers and TSS   |
| 6.5.4.2   | Sulfadoxine + pyrimethamine tablet 500mg + 25mg  | Use instead of deleted sulphadiazine and pyrimethamine                                  |
| 7.1.3     | Paracetamol suppository 125mg [c]  | Required paediatric presentation  |
| 8.1.3     | a) Methylprednisolone PFI 125mg (as sodium succinate)<br>b) Methylprednisolone PFI 500mg (as sodium succinate)                     | Kidney transplantation  |
| 8.1.4     | a) Mycophenolic acid tablet 180mg (as mycophenolate sodium) e/c<br>b) Mycophenolic acid tablet 360mg (as mycophenolate sodium) e/c | Kidney transplantation; better side-effect profile than mofetilsalt                     |

## KEML 2016

| #      | Item Added   | Indication/Notes  |
|--------|--|---|
| 8.1.5  | Prednisolone tablet 5mg  | Kidney transplantation  |
| 8.1.6  | a) Tacrolimus concentrate for IV infusion 5mg/1mL amp                  | Kidney transplantation (induction phase; when vomiting, and oral route not possible in postoperatively) |
|        | b) Tacrolimus capsule 500 micrograms                                   | Kidney transplantation; various strengths required for titrated dose reduction                          |
|        | c) Tacrolimus capsule 1mg  |   |
|        | d) Tacrolimus capsule 5mg  |   |
| 8.2.1  | Alendronic acid tablet 70mg  | See list entry for indications  |
| 8.2.6  | a) Capecitabine tablet 150mg   | See list entry for indications  |
|        | b) Capecitabine tablet 500mg   |   |
| 8.2.7  | b) Carboplatin injection 10mg/mL (45mL vial)                           | See list entry for indications  |
| 8.2.9  | b) Cisplatin injection 1mg/mL (100ml vial)                             | See list entry for indications  |
| 8.2.10 | a) Cyclophosphamide PFI 200mg vial                                     | See list entry for indications  |
| 8.2.12 | Dacarbazine PFI 200mg vial   | See list entry for indication; replaces 100mg vial  |
| 8.2.15 | a) Docetaxel injection 10mg/mL (2mL vial)                              | See list entry for indications  |
|        | b) Docetaxel injection 10mg/mL (8mL vial)                              |   |
| 8.2.16 | a) Doxorubicin PFI 10mg vial   | See list entry for indications  |
| 8.2.18 | a) Filgrastim injection 120 micrograms/0.2ml prefilled syringe         | See list entry for indications  |
|        | b) Filgrastim injection 300 micrograms/0.5ml prefilled syringe         |   |
| 8.2.20 | a) Gemcitabine PFI 200mg vial  | See list entry for indications  |
|        | b) Gemcitabine PFI 1g vial   |   |
| 8.2.21 | a) Hydroxycarbamide capsule 250mg                                      | See list entry for indication   |
| 8.2.22 | a) Ifosfamide PFI 1g vial  | See list entry for indications  |
|        | b) Ifosfamide PFI 2g vial  |   |
| 8.2.23 | Imatinib tablet 400mg  | See list entry for indications  |
| 8.2.24 | a) Irinotecan injection 20mg/mL (2mL vial)                             | See list entry for indication   |
|        | b) Irinotecan injection 20mg/mL (5mL vial)                             |   |
| 8.2.26 | Melphalan tablet 2mg   | See list entry for indications  |
| 8.2.27 | Mesna injection (solution for infusion) 100mg/mL (2mL amp)             | See list entry for indications  |
| 8.2.28 | Methotrexate PFI (preservative-free) 25mg/mL (20mL vial) (as sod.salt) | See list entry for indications  |

## KEML 2016

| #      | Item Added   | Indication/Notes                    |
|--------|--|-------------------------------------|
| 8.2.29 | a) Oxaliplatin inj. 5mg/mL (10mL vial)                         | See list entry for indications      |
| 8.2.30 | a) Paclitaxel concentrate for IV infusion 6mg/mL (5mL vial)    | See list entry for indications      |
|        | b) Paclitaxel concentrate for IV infusion 6mg/mL (16.7mL vial) |                                     |
| 8.2.32 | a) Rituximab injection 10mg/mL (10mL vial)                     | See list entry for indications      |
|        | b) Rituximab injection 10mg/mL (50mL vial)                     |                                     |
| 8.2.33 | Thalidomide capsule 100mg                                      | See list entry for indications      |
| 8.2.34 | a) Trastuzumab PFI 150mg vial                                  | See list entry for indications      |
|        | b) Trastuzumab PFI 440mg vial                                  |                                     |
| 8.2.35 | Vinblastine sulphate injection 1mg/mL (10mL vial)              | See list entry for indications      |
| 8.2.36 | a) Vinorelbine injection 10mg/mL (1mL vial)                    | See list entry for indications      |
|        | a) Vinorelbine injection 10mg/mL (5mL vial)                    |                                     |
| 8.2.37 | a) Zoledronic acid injection 10mg/mL (1mL vial)                | See list entry for indications      |
|        | b) Zoledronic acid injection 10mg/mL (5mL vial)                |                                     |
| 8.3.1  | Anastrozole tablet 1mg   | Post-menopausal breast cancer       |
| 8.3.2  | Bicalutamide tablet 50mg                                       | See list entry for indication       |
| 8.3.3  | b) Dexamethasone tablet 500 micrograms                         | See list entry for indication       |
| 8.3.5  | a) Goserelin implant 3.6mg                                     | See list entry for indications      |
|        | b) Goserelin implant 10.8mg                                    |                                     |
| 8.3.7  | Methylprednisolone PFI 500mg                                   | See list entry for indications      |
| 8.3.8  | a) Prednisolone oral liquid 15mg/5mL [c]                       | See list entry for indications      |
| 8.3.9  | Tamoxifen tablet 20mg (as citrate)                             | See list entry for indications      |
| 8.4.1  | Finasteride tablet 5mg   | Benign prostatic hyperplasia        |
| 8.4.2  | Tamsulosin tablet 400 micrograms                               |                                     |
| 9.2    | a) Levodopa + carbidopa tablet 100mg + 10mg                    | Parkinsonism (1 <sup>st</sup> line) |
|        | b) Levodopa + carbidopa tablet 250mg + 25mg                    |                                     |
| 9.3    | a) Pramipexole tablet 180 micrograms                           | Refractory parkinsonism             |
|        | b) Pramipexole tablet 700 micrograms                           |                                     |
| 10.1.1 | Ferrous salt oral liquid (drops)                               | Required paediatric presentation    |



## KEML 2016

| #        | Item Added  | Indication/Notes  |
|----------|---|---|
|          | 25mg/mL elemental iron  |   |
| 10.1.3   | a) Folic acid tablet 400 micrograms                                     | Periconceptual prevention of first occurrence of neural tube defects                              |
| 10.2.2   | a) Phytomenadione (Vit K1) injection 1mg/1mL amp [c]                    | Prevention of neonatal vitamin K deficiency bleeding (replaces 10mg/0.2mL amp)                    |
|          | b) Phytomenadione (Vit K1) injection 10mg/mL (5mL amp)                  | Warfarin-associated bleeding  |
| 10.2.4   | Tranexamic acid injection 100mg/mL (5mL amp)                            | Prevention/treatment of bleeding associated with excessive fibrinolysis                           |
| 10.2.5   | b) Warfarin sodium tablet 2mg   | For improved dosing flexibility   |
| 10.2.6   | a) Enoxaparin injection (prefilled syringe) 40mg/0.4mL                  | Safe, effective and more convenient alternative to heparin; no requirement for routine monitoring |
|          | b) Enoxaparin injection (prefilled syringe) 80mg/0.8mL                  |   |
| 10.2.9   | a) Warfarin sodium tablet 0.5mg   | <i>Required low dose presentation, especially for paediatric use</i>                              |
| 10.3.1   | Deferasirox tablet 500mg  | Iron overload   |
| 10.3.2   | Deferoxaminemesilate PFI 500mg vial                                     | Iron overload   |
| 10.3.3   | a) Hydroxycarbamide capsule 250mg                                       | Sickle cell disease   |
|          | b) Hydroxycarbamide capsule 500mg                                       |   |
| 11.1.1   | Plasma, fresh frozen  |   |
| 11.1.2   | Platelets   | New section added in line with WHO Model List   |
| 11.1.3   | Red blood cells   |   |
| 11.1.4   | Whole blood   |   |
| 11.2.1.4 | a) Normal immunoglobulin injection IV 5% protein solution (100mL vial)  |   |
|          | b) Normal immunoglobulin injection IV 10% protein solution (100mL vial) |   |
| 11.3.1   | Polygeline IV infusion 3.5% (500mL)                                     | Plasma volume expansion; replaces dextran 70%   |
| 12.1.1   | a) Carvedilol tablet 6.25mg   | Replace atenolol tablet 50mg; improved benefit/risk profile                                       |
|          | b) Carvedilol tablet 12.5mg   |   |
| 12.1.3   | Isosorbide dinitrate tablet 20mg  | Useful longer acting vasodilator  |
| 12.2.1   | a) Carvedilol tablet 6.25mg   | Replace atenolol tablet 50mg; improved benefit/risk profile                                       |
|          | b) Carvedilol tablet 12.5mg   |   |
| 12.2.4   | b) Verapamil tablet 80mg (scored)                                       | Replaces 40mg for better dose flexibility   |
| 12.2.6   | Epinephrine injection 100micrograms/mL (10mL amp)                       | Cardiac arrest  |
| 12.3.2   | a) Carvedilol tablet 6.25mg   | Replaces atenolol tablet 50mg; improved benefit/ risk profile                                     |
|          | b) Carvedilol tablet 12.5mg   |   |
| 12.3.6   | Losartan tablet 50mg  | 1 <sup>st</sup> line antihypertensive with improved   |

## KEML 2016

| #        | Item Added   | Indication/Notes   |
|----------|--|--|
|          |  | adverse effect profile and prolonged action                    |
| 12.4.1   | a) Carvedilol tablet 6.25mg<br>b) Carvedilol tablet 12.5mg                     | Useful additions as per WHO Model List                         |
| 12.4.3   | b) Furosemide oral liquid<br>20mg/5mL [c]                                      | Useful paediatric presentation                                 |
| 12.4.5   | Spironolactone tablets 25mg (scored)   | Useful addition as per WHO ML                                  |
| 12.5.1.2 | Clopidogrel tablet 25mg  | Useful addition as per WHO ML                                  |
| 12.6.1   | Atorvastatin tablet 20mg (scored)  | Useful addition as per WHO ML                                  |
| 13.1.2   | TerbinafineHCl cream 1%  | Refractory fungal infections                                   |
| 13.3.2   | Clobetasone butyrate ointment 0.05%  | Very potent topical steroid                                    |
| 13.3.3   | Crotamiton cream 10%   | Pruritis (especially after scabies)                            |
| 13.3.4   | Desonide gel 0.05%   | Mild topical steroid   |
| 13.3.6   | Mometasonefuroate ointment 0.1%  | Potent topical steroid   |
| 13.3.7   | Tacrolimus ointment 0.03%  | Moderate-severe atopic eczema, especially if refractory        |
| 13.5.1   | Benzoyl peroxide gel 5%  | Acne vulgaris  |
| 13.5.2   | Coal tar + salicylic acid ointment<br>2% + 2%                                  | Psoriasis  |
| 13.6.2   | Crotamiton cream 10%   | Scabies and related pruritis                                   |
| 13.6.3   | Ivermectin tablet 6mg (scored)   | Refractory scabies   |
| 13.7.2   | White soft paraffin 100%   | Jiggers  |
| 13.8.1   | Sunscreening cream or lotion<br>UVB-SPF 30+                                    | Albinism & photodermatoses                                     |
| 14.1.1   | Fluorescein test strip 0.6mg   | Replaces fluorescein eye drops 1%                              |
| 14.2.4   | Iopromide injection (solution for IV<br>infusion) 150-370mg iodine/mL          | Required radiocontrast media                                   |
| 14.3.1   | Gadobutrol IV injection (solution)<br>1 mmol/mL                                | New section: MRI contrast media                                |
| 14.3.2   | Gadodiamide IV injection (solution)<br>0.5 mmol/mL                             |  |
| 14.3.3   | GadopentatedimeglumineIV injection<br>(solution) 0.5 mmol/mL                   |  |
| 15.1.1   | b) Chlorhexidine gel 4%<br>(as digluconate 7.1%) [c]                           | Umbilical cord care  |
| 15.2.1   | Alcohol-based hand rub solution,<br>isopropyl alcohol 75%<br>(500mL dispenser) | Hand hygiene; key element of infection<br>prevention & control |
| 16.2     | b) Furosemide oral liquid [c]<br>20mg/5mL                                      | For paediatric use   |
| 16.5     | Spironolactone tablet 25mg   | Potassium-sparing diuretic                                     |
| 17.1.1   | Lansoprazole dispersible tablet 15mg   | For paediatric use   |

## KEML 2016

| #        | Item Added  | Indication/Notes   |
|----------|---|--|
| 17.1.2   | b) Omeprazole PFI 40mg vial   | Severe peptic ulcer; and peptic ulcer when oral route is not possible                                      |
| 17.2.2   | a) Domperidone oral liquid 5mg/5mL  | Alternative for young children who cannot tolerate metoclopramide or who require an oral liquid antiemetic |
|          | b) Domperidone tablet 10mg  | Alternative for adult patients who cannot tolerate metoclopramide  |
| 17.2.4   | a) Ondansetron injection 2mg/mL base as HCl (2mL amp)                                       | Recommended 1 <sup>st</sup> line treatment for post-operative nausea & vomiting (PONV)                     |
|          | b) Ondansetron tablet (orally disintegrating) 4mg (base equivalent)                         |  |
| 17.2.5   | Dexamethasone tablet 500 micrograms   | Continuation oral steroid after initial parenteral therapy   |
| 17.3.1   | Mesalazine tablet 400mg (e/c)   | Supersedes sulfasalazine (deleted); improved side-effect profile   |
| 17.3.2   | Prednisolone tablet 5mg   | Chronic inflammatory bowel disease   |
| 17.4.1   | b) Bisacodyl suppository 10mg   | Alternative presentation when oral route not appropriate   |
| 17.5.2   | ORS (4 sachets) + zinc sulphate tablets 20mg dispersible (10) co pack                       | Required for updated treatment protocols   |
| 17.5.3   | Rehydration solution for malnutrition (ReSoMal) PFOL (sachet for 1L)                        | Required for updated treatment protocols   |
| 18.3.1.2 | Levonorgestrel tablet 30 micrograms   | Required for current family planning protocols   |
| 18.3.2.1 | Estradiolcypionate + medroxyprogesterone acetate injection 5mg + 25mg                       | Required for current family planning protocols   |
| 18.3.2.2 | b) Medroxyprogesterone acetate (DMPA) depot injection (SC) 104mg/0.65mL (prefilled syringe) | Required for current family planning protocols   |
| 18.3.3.2 | Levonorgestrel-releasing Intrauterine system (LNG-IUS), reservoir with 52mg                 | Required for current FP protocols  |
| 18.3.6.1 | Progesterone-releasing vaginal ring 2.074g  | Required for current FP protocols  |
| 18.5.2   | Gliclazide tablet 40mg  | For patients >60 years & as 2 <sup>nd</sup> line in others if glibenclamide not suitable                   |
| 18.7.1   | Medroxyprogesterone acetate tablet 5mg  | For menstrual conditions and endometriosis   |
| 18.8.3   | Lugol's iodine oral liquid ~130mg total iodine/mL [c]                                       | For pre-operative use in hyperthyroidism   |

## KEML 2016

| #       | Item Added   | Indication/Notes   |
|---------|--|--|
| 18.8.4  | Propylthiouracil tablet 50mg   | For 2 <sup>nd</sup> line use if carbimazole not tolerated/recommended  |
| 19.3.3  | HPV vaccine injection (suspension) 1mL vial (2 doses)  | Required for current vaccination protocols   |
| 19.3.5  | Polio vaccine (IPV) injection 5mL vial (10 doses)  | Required for current vaccination protocols   |
| 19.3.7  | Rotavirus vaccine (oral suspension) 1.5mL (single dose)  | Required for current vaccination protocols   |
| 19.3.10 | Cholera vaccine (oral suspension) 1.5mL vial (single dose)   | For use in epidemics   |
| 19.3.16 | Varicella vaccine (PFI + diluent) 0.5mL vial (single dose)   | For use in high-risk groups  |
| 19.3.17 | Pneumococcal vaccine(23-valent adsorbed conjugate) injection (suspension) 0.5mL vial (single dose) | For specialist use in high-risk groups   |
| 20.1    | Atracuriumbesilate injection 10mg/mL   | Neuromuscular blocker (short-intermediate duration)  |
| 20.2    | Cisatracurium injection 2mg/mL (10mL vial)   | Neuromuscular blocker (intermediate duration; replaces vecuronium)   |
| 20.3    | Glycopyrronium bromide + neostigmine metilsulfate injection 500 micrograms + 2.5mg/1mL amp         | Reversal of non-depolarising neuromuscular blockade (especially young and elderlypatients)                   |
| 20.5    | Pancuronium bromide injection 2mg/mL   | Neuromuscular blocker (required for its long duration of effect)   |
| 21.1.3  | Aciclovir eye ointment 3%  | Ophthalmic herpes  |
| 21.1.4  | Azithromycindihydrate eye drops 1.5%   | Trachomatous conjunctivitis  |
| 21.1.5  | Ciprofloxacin eye drops 0.3% (as HCl)  | Corneal ulcers   |
| 21.1.6  | Econazole eye drops 1%   | Fungal keratitis   |
| 21.2.1  | b) Prednisolone tablet 5mg   | Ophthalmic malignancies  |
| 21.2.2  | Prednisolone eye drops 1% (acetate)  | Deeper ocular inflammation   |
| 21.2.3  | Ketorolac trometamol eye drops 0.5%  | Ocular inflammation where steroids are contraindicated   |
| 21.2.4  | Methylprednisolone PFI 1g vial (as sod.succinate)  | Optic neuritis   |
| 21.2.5  | Triamcinoloneacetone injection (aq.suspension) 40mg/1mL amp  | Severe allergic conjunctivitis,diabetic retinopathy, intermediate uveitis, post-op in paediatric eye surgery |
| 21.4.3  | Dorzolamide eye drops 2% (as HCl)  | Open-angle glaucoma, in patients resistant to beta-blockers  |
| 21.4.4  | Latanoprost eye drops 0.005%   | Raised intra-ocular pressure in open-angle glaucoma; ocular hypertension                                     |

## KEML 2016

| #        | Item Added   | Indication/Notes  |
|----------|--|---|
| 21.5.1   | Atropinesulfate eye drops 0.5%   | Replaces 1% as preferred strength   |
| 21.5.2   | Tropicamide eye drops 0.5%   | Short-term dilation   |
| 21.5.3   | Epinephrine eye drops 2% (as HCl)  | Rapid dilation during eye surgery in non-hypertensive patients                                    |
| 21.6.1   | Sodium cromoglicate eye drops 2%   | Allergic conjunctivitis, vernal kerato-conjunctivitis   |
| 21.7.1   | Bevacizumab injection 25mg/mL (4mL vial)                                   | Diabetic retinopathy  |
| 23.2.2   | Haemodialysis solutions, parenteral (of appropriate composition)           | Haemodialysis   |
| 24.1.1   | b) ChlorpromazineHCl tablet 50mg   | Especially for geriatrics when smaller doses may be required                                      |
| 24.1.2   | Flupentixoldecanoate injection (oily, depot) 20mg/mL (2mL amp)             | Combined antipsychotic + antidepressant effect  |
| 24.1.4   | Haloperidol oral liquid 2mg/mL   | Paediatric presentation and for clandestine administration <sup>1</sup> to uncooperative patients |
| 24.1.5   | Olanzapine tablet (scored) 10mg  | 2nd generation antipsychotic; much improved adverse effect profile                                |
| 24.1.6   | Zuclopenthixolacetate injection (oily) 50mg/1mL (2mL amp)                  | For calming agitated/aggressive patients  |
| 24.1.7   | ChlorpromazineHCl injection 25mg/mL (2mL amp) [c]                          | Specialist list when used in children   |
| 24.1.8   | a) Clozapine tablet (scored) 25mg<br>b) Clozapine tablet (scored) 100mg    | Useful 2 <sup>nd</sup> line option for unresponsive patients                                      |
| 24.1.9   | a) Haloperidol injection 5mg/1mL amp<br>b) Haloperidol tablet (scored) 5mg | Specialist list when used in children   |
| 24.1.10  | a) Risperidone tablet 500 micrograms<br>b) Risperidone tablet 2mg          | Useful 2 <sup>nd</sup> line option especially in persistently aggressive adult patients           |
| 24.2.1.3 | Fluoxetine tablet (scored) 20mg [c]  | Complementary list when used in children  |
| 24.2.1.4 | a) Mirtazapine tablet 15mg<br>b) Mirtazapine tablet 30mg                   | Useful 2 <sup>nd</sup> line option for adult patients with an improved adverse effect profile     |
| 24.2.2.2 | Lithium carbonate tablet 400mg (modified release)                          | Replaces tablet 300mg; improved adherence/management  |
| 24.2.2.3 | a) Valproic acid (sodium valproate) tablet 200mg (enteric-coated)          | Increased dosage flexibility  |
| 24.3.1   | Bromazepam tablet 3mg (scored)   | Anxiety with agitation (replaces diazepam)  |
| 24.4.1   | ClomipramineHCl capsule 25mg   | Obsessive-compulsive disorders  |
| 24.5.1   | Diazepam tablet 5mg  | Alcohol dependency  |
| 24.5.2   | a) Nicotine chewing gum 2mg  | Smoking cessation   |

<sup>1</sup>Only after obtaining written guardian consent

## KEML 2016

| #      | Item Added   | Indication/Notes  |
|--------|--|---|
| 24.5.3 | b) Nicotine chewing gum 4mg  | Alcohol dependence  |
|        | a) B vitamins high potency injection IM<br>b) B vitamins high potency injection IV                   |   |
| 24.5.4 | a) Buprenorphine + naloxone tablet (sublingual) 2mg + 500 micrograms                                 | Opioid dependence   |
|        | b) Buprenorphine + naloxone tablet (sublingual) 8mg + 2mg  |   |
| 24.5.6 | Naltrexone tablet 50mg   |   |
| 24.6.1 | Methylphenidate tablet 10mg  | Attention deficit hyperactivity disorder (ADHD)             |
| 25.1.5 | Formoterol fumarate + budesonide dry powder inhaler 6 micrograms + 200 micrograms/metered dose       | Refractory chronic asthma                                   |
| 25.1.6 | a) Ipratropium bromide inhalation (aerosol) 20 micrograms/metered dose                               | COPD and refractory paediatric asthma                       |
|        | b) Ipratropium bromide nebuliser solution 250 micrograms/1mL unit dose vial                          |   |
| 25.1.7 | a) Montelukast (as sod. salt) granules 4mg sachet  | Stepped management of asthma                                |
|        | b) Montelukast (as sod. salt) tablet 10mg  |   |
| 26.1.2 | ORS + zinc sulphate co-pack 500mL sachets (4) + zinc sulph tab 20mg (10)                             | Dehydration in children                                     |
| 26.1.3 | Rehydration solution for malnutrition (WHO formula - ReSoMal) sachet (powder for making 1L solution) | Dehydration in patients with malnutrition                   |
| 26.2.2 | b) Potassium chloride injectable solution 15% (10mL amp) [c]   | Severe hypokalaemia   |
| 26.2.6 | Sodium chloride injectable solution 3% (hypertonic) (10mL amp)                                       | Bronchiolitis in children; hyponatremia in renal conditions |
| 27.1   | Calcium carbonate tablet (chewable) 1.25g  | Calcium deficiency, eg. in chronic renal disease & rickets  |
| 27.3   | Cholecalciferol (Vit D <sub>3</sub> ) oral liquid (drops) 400 IU/mL [c]                              | Deficiency states   |
| 27.4   | Ergocalciferol (Vit D <sub>2</sub> ) tablet 1.25mg (50,000 IU)                                       | Deficiency states   |
| 27.5   | PyridoxineHCl (Vit B <sub>6</sub> ) tablet 50mg (scored)   | Replaces 25mg (was in Complementary List)                   |
| 27.8   | Ergocalciferol (Vit D <sub>2</sub> ) injection IM (oily)   | Severe deficiency states                                    |

## KEML 2016

| #      | Item Added  | Indication/Notes   |
|--------|---|--|
|        | 300,000 IU/1mL amp  |  |
| 28.1.2 | Hydrogen peroxide solution (ear drops) 5%   | Wax softening and removal  |
| 28.1.3 | Ciprofloxacin HCl + betamethasone sodium solution (ear drops) 0.3% + 0.1%   | Infected otitis externa with inflammation and eczema                   |
| 28.1.4 | Clotrimazole solution (ear drops) 1%  | Otitis externa with fungal infection                                   |
| 28.2.1 | Liquid paraffin nasal drops 100%  | Nasal canal dryness (eg.rhinitis sicca)                                |
| 28.2.2 | Sodium chloride nasal drops 0.9%  | Nasal congestion   |
| 28.2.3 | Budesonide nasal spray<br>100 micrograms/metered dose   | Allergic & vasomotor rhinitis  |
| 29.2.1 | Dexamethasone injection 4mg/mL<br>(as sodium phosphate)   | In new Section 29.2; for enhancing neonatal lung maturity              |
| 30.1.1 | Allopurinol tablet 300mg (scored)   | Replaces tablet 100mg  |
| 30.2.3 | Leflunomide tablet 20mg   | For use when methotrexate and sulfasalazine cannot be used             |
| 30.3.1 | Aspirin tablet 300mg (scored)   | In new Section 30.3 Juvenile joint disease                             |
| 31.3   | Total parenteral nutrition (TPN)<br>(amino acids + lipids + glucose + electrolytes) infusion (emulsion)<br>(triple-chamber) | Required for providing TPN   |
| 32.1   | Ready to use therapeutic food (RUTF)<br>oral paste standard formula<br>(500 kcal sachet)                                    |  |
| 32.2   | F-75 therapeutic milk PFOL for approx..<br>600mL (standard formula 102.5g sachet)   | In new Section 32: Preparations For managing Severe Acute Malnutrition |
| 32.2   | F-100 therapeutic milk PFOL for approx..<br>600mL (standard formula 114g sachet)  |  |

Deletions

| Section | Item Deleted   | Reason/Notes  |
|---------|--|---|
| 1.2     | Bupivacaine injection 0.25%                          | Not required, use 0.5% (dilute as required)                                       |
|         | Lignocaine injection 1%                              | 2% preferred (dilute if 1% required)  |
|         | Lignocaine HCl topical solution 4% (in spray bottle) | Replaced by lidocaine HCl topical solution 2% (spray bottle)                      |
|         | Lignocaine + adrenaline injection 1% + 1:80,000      | Not required  |
|         | Lignocaine dental cartridge 2%                       | Not required  |
|         | Lignocaine topical solution 10% spray                | Not required (use 2%)   |
| 1.3     | Diazepam injection 5mg/mL                            | Replaced by preferred midazolam preparations (faster recovery)                    |
|         | Diazepam tablet 5mg                                  |   |
|         | Promethazine oral liquid 5mg/5mL                     | Efficacy, obsolete (better alternatives available, eg. midazolam)                 |
|         | Hyoscine hydrobromide injection 400 micrograms/mL    | Not required (use atropine)   |
| 2.1     | Diclofenac injection 25mg/mL                         | Not recommended, increased risk of cardiovascular adverse effects (use ibuprofen) |
|         | Diclofenac suppository 100mg                         |   |
| 2.2     | Paracetamol suppository 60mg                         | Not required (use 125mg)  |
|         | Morphine oral liquid 10mg/5mL                        | Not required (use 1mg/mL or 10mg/mL)  |
| 2.3     | Morphine tablet 60mg (prolonged-release)             | Not required (use 30mg)   |
|         | Allopurinol tablet 100mg                             |   |
|         | Cyclizine injection 50mg/mL                          | Replaced by tablet 300mg (scored) in new section 30                               |
|         | Cyclizine 50mg                                       |   |
| 3       | Docosate sodium capsule 100mg                        | Not used/required (alternatives available)  |
|         | Docosate sodium oral liquid 50mg/5mL                 |   |
| 3       | Chlorphenamine injection 10mg/mL                     | Replaced by cetirizine (better adverse effect profile)                            |
|         | Chlorphenamine oral liquid 2mg/5mL                   |   |
|         | Prednisolone tablet 25mg                             | Not required for this indication  |
| 5       | Aminophylline injection 25mg/mL                      | Not recommended (safer & more effective alternatives available)                   |
|         | Diazepam injection 5mg/mL                            | Replaced by lorazepam injection   |
|         | Ethosuximide oral liquid                             | Not required  |



## KEML 2016

| Section | Item Deleted   | Reason/Notes  |
|---------|--|---|
| 6.1.1   | 250mg/5mL  | Not required  |
|         | Ethosuximide tablet 250mg  |   |
|         | Niclosamide tablet, chewable 500mg   |   |
| 6.1.2   | Ivermectin tablet, scored 6mg  | Not required  |
| 6.2.1   | Amoxicillin PFOL 125mg/5mL   | Replaced by tablet 250mg dispersible, scored (preferred presentation)                             |
|         | Amoxicillin + clavulanic acid PFOL 250mg + 62.5mg/5mL  | Replaced by DT, scored 200mg + 28.5mg   |
|         | Amoxicillin + clavulanic acid tablet 625mg   | Replaced by tablet 875mg + 125mg  |
|         | Ampicillin PFI 500mg   | Minimal use, high levels of resistance  |
|         | Benzathine penicillin PFI 1.44g (2.4MU) in 5mL vial  | Replaced by 900mg (1.2MU) vial (preferred presentation)   |
|         | Benzylpenicillin PFI 3g (5MU) vial   | Not required (use 600mg 1MU vial)   |
|         | Cefuroxime injection 750mg vial<br>Cefuroxime tablet 250mg   | Not recommended, poorly tolerated, high cost (use amoxicillin + clavulanic acid)                  |
| 6.2.2   | Chloramphenicol capsule 250mg<br>Chloramphenicol injection PFI 1g<br>Chloramphenicol oral liquid 125mg/5mL | Not required for updated protocols  |
|         | Erythromycin PFOL 125mg/5mL  | Replaced by preferred azithromycin (better tolerated, simpler dose regime, improved cost benefit) |
|         | Erythromycin tablet 250mg  |   |
|         | Metronidazole tablet 400mg   | Use 200mg (improved cost benefit)   |
| 6.2.4   | Isoniazid tablet (scored) 50mg   | Replaced by oral liquid 50mg/5mL  |
|         | Ethambutol oral liquid 25mg/mL   | Not required  |
|         | Ofloxacin tablet 200mg   | Not required (use levofloxacin or moxifloxacin)   |
| 6.3     | Streptomycin PFI 1g vial   | Not required for updated TB regimes   |
|         | Clotrimazole vaginal tablet 200mg  | Replaced by 500mg (single dose, improved adherence)   |
| 6.4.2.1 | Abacavir oral liquid 100mg/5mL   | Not required in updated treatment protocols   |
|         | Didanosine PFOL 100mg packet   | Not required in updated treatment protocols   |
|         | Didanosine PFOL 167mg packet   | Not required in updated treatment protocols   |
|         | Didanosine PFOL 250mg packet   | Not required in updated treatment protocols   |
|         | Didanosine capsule 125mg (e/c, unbuffered)   | Not required in updated treatment protocols   |
|         | Didanosine capsule 200mg (e/c, unbuffered)   | Not required in updated treatment protocols   |
|         | Didanosine capsule 250mg (e/c, unbuffered)   | Not required in updated treatment protocols   |

## KEML 2016

| Section | Item Deleted   | Reason/Notes  |
|---------|--|---|
|         | Didanosine tablet 25mg<br>(buffered, chewable, dispersible)              | Not required in updated treatment protocols                                       |
|         | Didanosine tablet 50mg<br>(buffered, chewable, dispersible)              | Not required in updated treatment protocols                                       |
|         | Didanosine tablet 100mg<br>(buffered, chewable, dispersible)             | Not required in updated treatment protocols                                       |
|         | Didanosine tablet 150mg<br>(buffered, chewable, dispersible)             | Not required in updated treatment protocols                                       |
|         | Didanosine tablet 200mg<br>(buffered, chewable, dispersible)             | Not required in updated treatment protocols                                       |
|         | Stavudine capsule 15mg   | Not required in updated treatment protocols                                       |
|         | Stavudine capsule 20mg   | Not required in updated treatment protocols                                       |
|         | Stavudine capsule 30mg   | Not required in updated treatment protocols                                       |
|         | Tenofovir tablet 300mg   | Not required in updated treatment protocols                                       |
|         | Zidovudine capsule 100mg   | Not required in updated treatment protocols                                       |
|         | Zidovudine oral liquid 50mg/5mL  | Not required in updated treatment protocols                                       |
|         | Zidovudine tablet 300mg  | Not required in updated treatment protocols                                       |
| 6.4.2.2 | Efavirenz capsule 50mg   | Not required in updated treatment protocols                                       |
|         | Efavirenz capsule 100mg  | Not required in updated treatment protocols                                       |
|         | Efavirenz oral liquid 150mg/5mL  | Not required in updated treatment protocols                                       |
| 6.4.2.3 | Lopinavir + ritonavir capsule<br>133.3mg + 33.3mg                        | Not required in updated treatment protocols                                       |
|         | Lopinavir + ritonavir tablet<br>200mg + 50mg                             | Not required in updated treatment protocols                                       |
| 6.4.2.4 | Efavirenz + emtricitabine +<br>tenofovir tablet<br>600mg + 200mg + 300mg | Not required in updated treatment protocols                                       |
|         | Lamivudine + nevirapine +<br>stavudine tablet<br>150mg + 200mg + 30mg    | Not required in updated treatment protocols                                       |
|         | Lamivudine + stavudine tablet<br>300mg + 300mg                           | Not required in updated treatment protocols                                       |
| 6.5.3.1 | Artemether oily injection<br>80mg/1mL amp                                | No longer required (difficult to administer,<br>use artesunate)                   |
|         | Doxycycline tablet 100mg   | No longer required for malaria treatment<br>(use AL) but retained for prophylaxis |
|         | Quinine injection 300mg/mL   | No longer required (use artesunate)   |
| 6.5.4   | Dapsone tablet 100mg   | Not used/required (use cotrimoxazole +<br>sulfadoxine/pyrimethamine [SP])         |
|         | Pyrimethamine tablet 25gm  |   |
|         | Sulphadiazine tablet 500mg   |   |
| 8.2     | Dacarbazine PFI 100mg  | Replaced by PFI 200mg vial (as citrate)   |

## KEML 2016

| Section | Item Deleted   | Reason/Notes   |
|---------|--|--|
|         | a) Etoposide capsule 100mg                                   | Not used/required (use injection)  |
|         | Vincristine PFI 1mg vial                                     |  |
|         | Vincristine PFI 5mg vial                                     | Not used/required  |
| 8.3     | Methylprednisolone injection (aq. suspension) 40mg/1mL       | Replaced by PFI 500mg vial (as sod.succinate)  |
| 9       | Biperiden tablet 2mg (HCl)                                   | Not used/required (benzhexol retained)   |
| 10.2    | Phytomenadione (Vit K1) injection 10mg/mL in 0.2mL amp       | Replaced by 1mg/1mL amp presentation   |
| 11.1    | Dextran 70 injection solution 6%                             | Replaced by preferred polygeline IV infusion 3.5% 500mL pack   |
| 12.1    | Atenolol tablet 50mg   | Replaced by carvedilol tablet 6.25mg and 12.5mg (better benefit/risk profile)                        |
|         | Verapamil tablet 40mg  | Not used/required  |
| 12.2    | Atenolol tablet 50mg   | Replaced by carvedilol tablet 6.25mg and 12.5mg (better benefit/risk profile)                        |
|         | Verapamil tablet 40mg  | Replaced by 80mg (scored)  |
| 12.3    | Atenolol tablet 50mg   | Replaced by carvedilol tablet 6.25mg and 12.5mg (better benefit/risk profile)                        |
| 12.5    | Streptokinase PFI 750,000 IU vial                            | Not used, not cost-effective   |
| 13.3    | Calamine lotion 15%  | Obsolete preparation (use crotamiton cream or appropriate steroid cream)                             |
|         | Coal tar solution 5%   | Not available/used (use coal tar 2% + salicylic acid 2% ointment)                                    |
| 13.5    | Dithranol ointment 1%  | Not available/required   |
|         | Salicylic acid solution 5%                                   | Not available/required   |
| 14.1    | Fluorescein eye drops 1%                                     | Replaced by fluorescein test strips 0.6mg  |
| 16.4    | Mannitol injectable solution 10%                             | Not required; use 20%  |
|         | Magnesium trisilicate co tablet, chewable 370mg              | No evidence of benefit compared with placebo (safe and effective alternative available - omeprazole) |
|         | Ranitidine injection 25mg/mL                                 |  |
| 17      | Ranitidine tablet 150mg                                      | Superseded by omeprazole   |
|         | Promethazine oral liquid 5mg/5mL                             | Not used/required (less effective than available alternatives)                                       |
|         | Sulfasalazine suppository 500mg                              | Not used/required  |
|         | Sulfasalazine tablet 500mg                                   | Superseded by mesalazine   |
| 18.1    | Hydrocortisone tablet 5mg                                    | Not used/required  |
|         | Prednisolone tablets 5mg                                     | Not used/required  |
| 18.3.1  | Ethinylestradiol + norethisterone tablet 35 micrograms + 1mg | Use ethinylestradiol + levonorgestrel tablet 30 micrograms + 150 micrograms                          |
| 18.3.2  | Norethisterone enantate oily                                 | Not used in current family planning protocols  |

## KEML 2016

| Section | Item Deleted   | Reason/Notes   |
|---------|--|--|
| 20      | solution 200mg/1mL ampoule<br>Vecuronium bromide PFI 10mg vial   | Replaced by cisatracurium (better adverse effect profile)  |
| 21.4    | Pilocarpine eye drops 2%<br>Timolol eye drops 0.25%  | Rarely used (use dorzolamide eye drops)<br>Not useful/effective (use 0.5%)   |
| 21.5    | Atropinesulfate eye drops 1%   | Not preferred (use 0.5%)   |
| 24.2.2  | Carbamazepine tablet 100mg<br>Lithium carbonate tablet 300mg   | Not required (use 200mg scored)<br>Replaced by 400mg (modified release)  |
| 24.3    | Diazepam tablet 5mg  | Replaced by bromazepam tablet 3mg (scored)   |
| 24.5    | Clonidine tablet 100 micrograms  | Not being used   |
| 25.1    | Beclomethasone inhalation (aerosol) 50 micrograms/dose<br>Salbutamol oral liquid 2mg/5mL<br>Salbutamol tablet 4mg  | Not required (use 100 micrograms/dose inhaler)<br>Not recommended<br>Not recommended   |
| 26.1    | Potassium chloride powder for dilution to make 7.5% oral solution  | Not used   |
| 26.2    | Sodium hydrogen carbonate (bicarbonate) injectable solution 1.4% (isotonic)  | Not required   |
| 27      | Ascorbic acid tablet 50mg<br>Ergocalciferol oral drops 400 IU/0.6mL dose<br>Nicotinamide(Vit B <sub>3</sub> )tablet 50mg<br>Cholecalciferol tablet 10 micrograms (400 IU)<br>PyridoxineHCl (Vit B <sub>6</sub> ) tablet 10mg<br>Pyridoxine HCl (Vit B <sub>6</sub> ) tablet 25mg | Not required<br>Replaced by cholecalciferol oral liquid (drops) 400 IU/mL [c]<br>Not required<br>Replaced by oral liquid (drops) 400 IU/mL [c]<br>Replaced by tablet 50mg (scored) |
| 28      | Acetic acid solution (ear drops) 2% in alcohol<br>Polyvidone iodine mouthwash 1%   | Not used/required  |
| 29      | Aminoacids infusion 3%   | Not used/required (other strengths available)  |

# Kenya Essential Medicines List 2016

| #   | Drug                                    | Dose-form                       | Size/strength                                     | Level |
|---|---|---------------------------------|---|-------|
| <b>1. ANAESTHETICS</b>  |   |                                 |   |       |
| <b>1.1 General anaesthetics &amp; oxygen</b>  |   |                                 |   |       |
| <b>1.1.1 Inhalational anaesthetics</b>  |   |                                 |   |       |
| 1.1.1.1   | Halothane                               | Inhalation                      |   | 4     |
| 1.1.1.2   | Isoflurane                              | Inhalation                      |   | 4     |
| 1.1.1.3   | Medical air                             | Inhalation (medicinal gas)      |   | 4     |
| 1.1.1.4   | Nitrous oxide                           | Inhalation (medicinal gas)      |   | 4     |
| 1.1.1.5   | Oxygen                                  | Inhalation (medicinal gas)      |   | 2     |
| <b>1.1.2 Injectables</b>  |   |                                 |   |       |
| 1.1.2.1   | Ketaminehydrochloride                   | Injection                       | 50mg/mL (10mL vial)                               | 4     |
| 1.1.2.2   | Propofol <sup>2</sup>                   | Injection                       | 10mg/mL (20mL vial)                               | 4     |
| 1.1.2.3   | Thiopental sodium                       | PFI                             | 500mg vial  | 4     |
| <b>1.2 Local anaesthetics</b>   |   |                                 |   |       |
| 1.2.1   | BupivacaineHCl                          | Injection (preservative-free)   | a) 0.5% (10mL vial)                               | 3     |
|   |   | Injection (spinal) <sup>3</sup> | b) 0.5% (5mg/mL) + glucose 8% (80mg/mL) (4mL amp) |       |
| 1.2.2   | LidocaineHCl                            | Injection (preservative-free)   | a) 2% (30mL vial)                                 | 2     |
|   |   | Topical solution                | b) 2% (spray bottle)                              |       |
| 1.2.3   | LidocaineHCl + epinephrine (adrenaline) | Dental cartridge                | 2% + 1:80,000 (1.8mL cartridge)                   | 4     |
| <b>Specialist List</b>  |   |                                 |   |       |
| 1.2.4   | <i>EphedrineHCl</i> <sup>4</sup>        | <i>Injection</i>                | <i>30mg/1mL amp</i>                               |       |
| <b>1.3 Pre- and intra-operative medication and sedation for short-term procedures</b> |   |                                 |   |       |
| 1.3.1   | Atropine sulphate                       | Injection                       | 1mg/1mL amp                                       | 3     |
| 1.3.2   | Chlorphenamine maleate <sup>5</sup>     | Injection                       | 10mg/1mL amp                                      | 3     |
| 1.3.3   | Midazolam                               | a) Injection (as HCl)           | 1mg/mL(5mL vial)                                  | 3     |
|   |   | b) Oral liquid [c] <sup>6</sup> | 2mg/mL (as HCl)                                   | 3     |

<sup>2</sup> Thiopental may be used as an alternative where propofol is not available

<sup>3</sup> Also referred to as 'heavy spinal'; may be available with glucose 7.5% (75mg/mL)

<sup>4</sup> For specialist use in spinal anaesthesia during delivery for prevention of hypotension

<sup>5</sup> Use only for managing allergic reactions to morphine

| #   | Drug                            | Dose-form                                    | Size/strength                   | Level |
|---|---------------------------------|--|---------------------------------|-------|
| 1.3.4   | Morphine                        | c) Tablet                                    | 7.5mg (as maleate)              | 3     |
|   |                                 | Injection                                    | 10mg/1mL amp (HCl or sulphate)  | 3     |
| <b>Specialist List</b>  |                                 |  |                                 |       |
| 1.3.5   | Fentanyl <sup>7</sup>           | Injection (as citrate)                       | 50 micrograms/mL (2mL amp)      |       |
| <b>2. MEDICINES for PAIN and PALLIATIVE CARE</b>                              |                                 |  |                                 |       |
| <b>2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)</b> |                                 |  |                                 |       |
| 2.1.1   | Aspirin                         | Tablet                                       | 300mg                           | 2     |
| 2.1.2   | Ibuprofen <sup>8</sup>          | a) Oral liquid [c]                           | 100mg/5mL                       | 2     |
|   |                                 | b) Tablet                                    | 200mg                           | 2     |
| 2.1.3   | Paracetamol <sup>9</sup>        | a) Injection <sup>10</sup> (for IV infusion) | 10mg/mL (100mL vial)            | 4     |
|   |                                 | b) Oral liquid [c]                           | 125mg/5mL <sup>11</sup>         | 1     |
|   |                                 | c) Suppository [c]                           | 125mg                           | 2     |
|   |                                 | d) Tablet (scored)                           | 500mg                           | 1     |
| <b>2.2 Opioids</b>  |                                 |  |                                 |       |
| 2.2.1   | Codeine phosphate <sup>12</sup> | Tablet                                       | 30mg                            | 3     |
| 2.2.2   | Morphine <sup>13</sup>          | a) Injection                                 | 10mg/1mL amp (HCl or sulphate)  | 3     |
|   |                                 | Oral liquid (HCl or sulphate)                | b) 1mg/mL                       | 4     |
|   |                                 |  | c) 10mg/mL                      | 4     |
|   |                                 | d) Tablet (m/r)                              | 30mg (sulphate)                 | 4     |
| <b>2.3 Medicines for other common symptoms in palliative care</b>             |                                 |  |                                 |       |
| 2.3.1   | Amitriptyline                   | Tablet                                       | 25mg                            | 4     |
| 2.3.2   | Bisacodyl                       | a) Tablet                                    | 5mg                             | 4     |
|   |                                 | b) Suppository                               | 10mg                            | 4     |
| 2.3.3   | Dexamethasone                   | a) Injection                                 | 4mg/1mL amp (as sod. phosphate) | 4     |
|   |                                 | b) Tablet                                    | 2mg [c]                         | 4     |

<sup>6</sup> With graduated oral dispenser; 2.5mg/mL presentation may be available and used as an alternative

<sup>7</sup> Restricted for intra-operative use **only**

<sup>8</sup> Do not use for children <3 months old

<sup>9</sup> Not for anti-inflammatory use (no proven benefit)

<sup>10</sup> Use only for post-operative analgesia

<sup>11</sup> Alternative strength: 120mg/5mL

<sup>12</sup> Only use for adults

<sup>13</sup> Only to be prescribed by specially trained palliative care professionals

| #   | Drug                          | Dose-form                                   | Size/strength                                      | Level |
|---|-------------------------------|---|--|-------|
| 2.3.4   | Diazepam                      | a) Injection                                | 5mg/mL (2mL amp)                                   | 4     |
|   |                               | b) Oral liquid                              | 2mg/5mL  | 4     |
|   |                               | c) Gel or rectal solution <sup>14</sup> [c] | 5mg/mL (0.5mL tube)                                | 4     |
|   |                               | d) Tablet (scored)                          | 5mg  | 4     |
| 2.3.5   | Gabapentin                    | Tablet                                      | 300mg  | 4     |
| 2.3.6   | Haloperidol                   | a) Injection                                | 5mg/1mL amp  | 4     |
|   |                               | b) Tablet                                   | 5mg  | 4     |
| 2.3.7   | Hyoscine butylbromide         | Injection                                   | 20mg/1mL amp                                       | 4     |
| 2.3.8   | Hyoscine hydrobromide [c]     | Injection                                   | 400 micrograms/1mL amp                             | 4     |
| 2.3.9   | Lactulose [c]                 | Oral liquid                                 | 3.1-3.7mg/5mL                                      | 4     |
| 2.3.11  | Loperamide                    | Tablet                                      | 2mg  | 4     |
| 2.3.12  | Metoclopramide                | a) Injection                                | 5mg/mL (2mL amp)                                   | 4     |
|   |                               | b) Oral liquid                              | 5mg/5mL  | 4     |
|   |                               | c) Tablet                                   | 10mg   | 4     |
| 2.3.13  | Midazolam                     | Injection                                   | a) 1mg/mL  | 4     |
|   |                               |   | b) 5mg/mL  | 4     |
|   |                               | c) Oral liquid                              | 2mg/mL [c]   | 4     |
|   |                               | d) Tablet                                   | 7.5mg  | 4     |
| 2.3.14  | Ondansetron [c] <sup>15</sup> | a) Injection                                | 2mg/mL (2mL amp) (as HCl)                          | 4     |
|   |                               | b) Tablet                                   | 4mg (as HCl)                                       | 4     |
| <b>3. ANTIALLERGICS and MEDICINES used in ANAPHYLAXIS</b> |                               |   |  |       |
| 3.1   | CetirizineHCl                 | a) Oral liquid                              | 5mg/5mL  | 2     |
|   |                               | b) Tablet                                   | 10mg   | 2     |
| 3.2   | Dexamethasone                 | Injection                                   | 4mg/1mL amp (as disod. phosphate)                  | 4     |
| 3.3   | Epinephrine (adrenaline)      | Injection                                   | 1mg/1mL amp <sup>16</sup> (as HCl or hyd.tartrate) | 2     |
| 3.4   | Hydrocortisone                | PFI   | 100mg vial (as sod. succinate)                     | 2     |
| 3.5   | Prednisolone                  | a) Oral liquid [c]                          | 15mg/5mL   | 4     |
|   |                               | b) Tablet                                   | 5mg  | 4     |

<sup>14</sup> If not available, use diazepam injection solution 5mg/mL instead, administered rectally by syringe – *without the needle!*

<sup>15</sup> Use only in children >1 month old

<sup>16</sup> Strength may also be expressed as 1 in 1,000 or 0.1%

| #   | Drug                              | Dose-form                    | Size/strength                 | Level |
|---|-----------------------------------|------------------------------|-------------------------------|-------|
| <b>4. ANTIDOTES and OTHER SUBSTANCES used in POISONINGS</b> |                                   |                              |                               |       |
| <b>4.1 Non-specific</b>                                     |                                   |                              |                               |       |
| 4.1.1   | Activated charcoal                | PFOL                         | 50g                           | 2     |
| <b>4.2 Specific</b>   |                                   |                              |                               |       |
| 4.2.1   | Acetylcysteine                    | Injection                    | 200mg/mL (10mL amp)           | 4     |
| 4.2.2   | Atropine sulphate                 | Injection                    | 1mg/1mL amp                   | 4     |
| 4.2.3   | Deferasirox                       | Tablet                       | a) 100mg                      | 4     |
|   |                                   |                              | b) 400mg                      | 4     |
| 4.2.4   | Flumazenil                        | Injection                    | 100 micrograms/mL (5mL amp)   | 4     |
| 4.2.5   | Naloxone hydrochloride            | Injection                    | 400 micrograms/1mL amp        | 4     |
| 4.2.6   | Protamine sulphate                | Injection                    | 10mg/mL (5mL amp)             | 4     |
| <b>Specialist List</b>                                      |                                   |                              |                               |       |
| 4.2.7   | Deferoxaminemesilate              | PFI                          | 500mg vial                    |       |
| 4.2.8   | Dimercaprol <sup>17</sup>         | Injection (in oil)           | 50mg/mL (2mL amp)             |       |
| 4.2.9   | Ethanol <sup>18</sup>             | a) Injection                 | 100% (10mL amp) <sup>19</sup> |       |
|   |                                   | b) Oral liquid <sup>20</sup> | 95-96%                        |       |
| 4.2.10  | Fomepizole sulphate               | Injection                    | 5mg/mL (20mL amp)             |       |
| 4.2.11  | Penicillamine <sup>21</sup>       | Tablet                       | 250mg                         |       |
| 4.2.12  | Pralidoxime chloride              | PFI                          | 1g vial                       |       |
| 4.2.13  | Sodium calcium edetate            | Injection                    | 200mg/mL (5mL amp)            |       |
| 4.2.14  | Sodium nitrite <sup>22</sup>      | Injection                    | 30mg/mL (10mL amp)            |       |
| 4.2.15  | Sodium thiosulphate <sup>23</sup> | Injection                    | 250mg/mL (50mL amp)           |       |
| 4.2.16  | Succimer <sup>24</sup>            | Capsule                      | 100mg                         |       |
| <b>5. ANTICONVULSANTS/ANTIEPILEPTICS</b>                    |                                   |                              |                               |       |
| 5.1   | Carbamazepine                     | a) Oral liquid [c]           | 100mg/5mL                     | 4     |
|   |                                   | b) Tablet                    | 200mg (cross-                 | 4     |

<sup>17</sup>To be phased out as better alternatives are available

<sup>18</sup>Pharmaceutical grade (ie. BP, EP, USP); for use in methanol poisoning

<sup>19</sup> Also known as dehydrated or absolute alcohol; for administration as a 10% solution in glucose 5% IV infusion

<sup>20</sup>For dilution (1 part + 4 parts water) before use as a 20% solution; if unavailable use ethanol 40% solution (eg. vodka)

<sup>21</sup> Use with close monitoring

<sup>22</sup> Use focused on areas where cyanide poisoning is more prevalent

<sup>23</sup> Use focused on areas where cyanide poisoning is more prevalent

<sup>24</sup> Also called dimercaptosuccinic acid (DMSA)



| #  | Drug  | Dose-form                            | Size/strength                     | Level |
|--|---|--------------------------------------|-----------------------------------|-------|
|  |   |                                      | scored)                           |       |
| 5.2  | Diazepam [c]                                | Gel or rectal solution <sup>25</sup> | 5mg/mL (0.5mL tube)               | 2     |
| 5.3  | Gabapentin                                  | Tablet                               | 300mg                             | 4     |
| 5.4  | Lorazepam <sup>26</sup>                     | Injection                            | 4mg/1mL amp                       | 2     |
| 5.5  | Magnesium sulphate <sup>27</sup>            | Injection                            | 500mg/mL (50%) (10mL amp))        | 2     |
| 5.6  | Phenobarbital sodium                        | Injection                            | a) 30mg/1mL amp [c] <sup>28</sup> | 2     |
|  |   |                                      | b) 200mg/1mL amp                  | 2     |
|  |   | c) Tablet (scored)                   | 30mg                              | 2     |
| 5.7  | Phenytoin sodium                            | a) Injection                         | 50mg/mL (5mL vial)                | 4     |
|  |   | b) Oral liquid                       | 30mg/5mL                          | 4     |
|  |   | Tablet                               | c) 25mg                           | 4     |
|  |   |                                      | d) 100mg                          | 4     |
| 5.8  | Valproic acid (sodium valproate)            | a) Oral liquid                       | 200mg/5mL                         | 4     |
|  |   | Tablet (e/c)                         | b) 200mg                          | 4     |
|  |   |                                      | c) 500mg                          | 4     |
| <b>Specialist List</b>                                 |   |                                      |                                   |       |
| 5.9  | Lamotrigine                                 | Tablet                               | a) 25mg<br>b) 100mg               |       |
| <b>6. ANTI-INFECTIVES</b>                              |   |                                      |                                   |       |
| <b>6.1 Anthelmintics</b>                               |   |                                      |                                   |       |
| <b>6.1.1 Intestinal anthelmintics</b>                  |   |                                      |                                   |       |
| 6.1.1.1  | Albendazole <sup>29</sup>                   | Tablet (chewable)                    | 400mg                             | 1     |
| 6.1.1.2  | Praziquantel                                | Tablet                               | 600mg                             | 2     |
| <b>6.1.2 Antifilarials</b>                             |   |                                      |                                   |       |
| 6.1.2.1  | Albendazole <sup>30</sup>                   | Tablet (chewable)                    | 400mg                             | 1     |
| 6.1.2.2  | Diethylcarbamazine dihydrogen citrate (DEC) | Tablet (scored)                      | 100mg                             | 4     |
| <b>6.1.3 Antischistosomes and other antitrepatodes</b> |   |                                      |                                   |       |

<sup>25</sup> If not available, use diazepam injection solution 5mg/mL instead, administered rectally by syringe – *without the needle!*

<sup>26</sup> Use always with close monitoring

<sup>27</sup> Use only in management of pre-eclampsia; provides 5g per 10mL amp

<sup>28</sup> Use in paediatric emergencies

<sup>29</sup> Do not use in 1<sup>st</sup> trimester

<sup>30</sup> Do not use in 1<sup>st</sup> trimester

| #                                 | Drug  | Dose-form                    | Size/strength         | Level |
|-----------------------------------|---|------------------------------|-----------------------|-------|
| 6.1.3.1                           | Praziquantel  | Tablet (scored)              | 600mg                 | 2     |
| <b>6.2 Antibacterials</b>         |   |                              |                       |       |
| <b>6.2.1 Beta Lactams</b>         |   |                              |                       |       |
| 6.2.1.1                           | Amoxicillin   | a) DT <sup>31</sup> (scored) | 250mg                 | 2     |
|                                   |   | b) Capsule                   | 500mg                 | 2     |
| 6.2.1.2                           | Amoxicillin + clavulanic acid <sup>32</sup>               | a) DT (scored)               | 200mg + 28.5mg        | 2     |
|                                   |   | b) Tablet                    | 875mg + 125mg (1g)    | 2     |
| 6.2.1.3                           | Benzathinebenzylpenicillin                                | PFI                          | 900mg (1.2MU) vial    | 2     |
| 6.2.1.4                           | Benzylpenicillin (sodium or potassium)                    | PFI                          | 600mg (1MU) vial      | 2     |
| 6.2.1.5                           | Cefazolin <sup>33</sup>                                   | PFI                          | 1g vial               | 4     |
| 6.2.1.6                           | Cefixime <sup>34</sup>                                    | Tablet                       | 400mg (as trihydrate) | 2     |
| 6.2.1.7                           | Ceftriaxone <sup>35,36</sup> (as sodium salt)             | Injection                    | a) 250mg [c]          | 4     |
|                                   |   |                              | b) 1g                 | 2     |
| 6.2.1.8                           | Flucloxacillin (as sodium salt)                           | a) Capsule                   | 250mg                 | 4     |
|                                   |   | b) PFI                       | 500mg vial            | 4     |
|                                   |   | c) PFOL                      | 125mg/5mL             | 4     |
| 6.2.1.9                           | Phenoxymethylpenicillin <sup>37</sup> (as potassium salt) | Tablet                       | 250mg                 | 3     |
| <b>Specialist List</b>            |   |                              |                       |       |
| 6.2.1.10                          | Ceftazidime <sup>38</sup> (as pentahydrate)               | PFI                          | a) 250mg vial         |       |
|                                   |   |                              | b) 1g vial            |       |
| 6.2.1.11                          | Imipenem + cilastin <sup>39</sup>                         | PFI                          | a) 250mg + 250mg vial |       |
|                                   |   |                              | b) 500mg + 500mg vial |       |
| <b>6.2.2 Other antibacterials</b> |   |                              |                       |       |

<sup>31</sup> Dispersible tablet

<sup>32</sup> Also called co-amoxiclav; strength may be expressed as the total of the components

<sup>33</sup> Use only in surgical prophylaxis (patients >1mth)

<sup>34</sup> Use at Level 2 restricted to syndromic management of STI only

<sup>35</sup> Do not administer with calcium; avoid in infants with hyperbilirubinaemia; only use if >41 weeks corrected gestational age

<sup>36</sup> Use at Level 2 restricted to STI syndrome management only

<sup>37</sup> Use only in sickle-cell prophylaxis and as an alternative to benzathine penicillin where this is not tolerated in prophylaxis of rheumatic heart disease

<sup>38</sup> For specialist 2<sup>nd</sup> line use only where required laboratory diagnostic support and clear antibiotic use protocols are available

<sup>39</sup> For specialist 2<sup>nd</sup> line use only in treatment of life-threatening hospital-based infections due to suspected or proven multi-drug resistant organisms; imipenem present as monohydrate, cilastin as sodium salt

| #                                      | Drug   | Dose-form                    | Size/strength                      | Level |
|--|--|------------------------------|------------------------------------|-------|
| 6.2.2.1                                | Azithromycin <sup>40</sup>                     | a) Tablet (scored)           | 250mg (anhydrous)                  | 2     |
|  |  | b) PFOL                      | 200mg/5mL                          | 2     |
| 6.2.2.2                                | Ciprofloxacin                                  | a) Oral liquid [c]           | 250mg/5mL (anhydrous)              | 3     |
|  |  | b) Tablet                    | 250mg (as HCl)                     | 2     |
| 6.2.2.3                                | Clarithromycin <sup>41</sup>                   | Tablet (scored)              | 500mg                              | 4     |
| 6.2.2.4                                | Cotrimoxazole(sulfamethoxazole + trimethoprim) | a) Injection <sup>42</sup>   | 96mg/mL (10mL amp)                 | 2     |
|  |  | b) Oral liquid               | 240mg/5mL                          | 2     |
|  |  | c) Tablet (scored)           | 480mg                              | 2     |
| 6.2.2.5                                | Doxycycline <sup>43</sup>                      | Tablet                       | 100mg (as hyclate)                 | 2     |
| 6.2.2.6                                | Gentamicin                                     | Injection (as sulphate)      | a) 10mg/mL (2mL vial)              | 2     |
|  |  |                              | b) 40mg/mL (2mL vial)              | 2     |
| 6.2.2.7                                | Metronidazole                                  | a) Injection                 | 5mg/mL (100mL vial)                | 2     |
|  |  | b) Oral liquid               | 200mg/5mL (as benzoate)            | 2     |
|  |  | c) Tablet (f/c)              | 200mg                              | 2     |
| 6.2.2.8                                | Nitrofurantoin                                 | Tablet                       | 100mg                              | 4     |
| 6.2.2.9                                | Tinidazole <sup>44</sup>                       | Tablet                       | 500mg                              | 2     |
| <b>Specialist List</b>                 |  |                              |                                    |       |
| 6.2.2.10                               | Ciprofloxacin                                  | Solution for IV infusion [c] | 2mg/mL (50mL bottle) (as lactate)  |       |
| 6.2.2.11                               | Clindamycin <sup>45</sup>                      | a) Capsule                   | 150mg (as HCl)                     |       |
|  |  | b) Injection                 | 150mg/mL (2mL vial) (as phosphate) |       |
|  |  | c) Oral liquid [c]           | 75mg/5mL (as palmitate)            |       |
| 6.2.2.12                               | Vancomycin <sup>46</sup>                       | PFI                          | 250mg vial (as HCl)                |       |
| <b>6.2.3Antileprotics<sup>47</sup></b> |  |                              |                                    |       |

<sup>40</sup> Use at Level 2 restricted to STI syndromic management and penicillin hypersensitive patient only

<sup>41</sup> Use only in combination drug regimes for treatment of *H. pylori* infection

<sup>42</sup> Use only in treatment of PCP and toxoplasmosis

<sup>43</sup> Use in children <8 years only for life-threatening infections if there is no alternative

<sup>44</sup> Useful longer-acting alternative to metronidazole in treatment regimes where single daily doses may be used to improve adherence

<sup>45</sup> For specialist use only in bone & joint infections and secondary bacterial infections in viral parotitis

<sup>46</sup> Use only in endocarditis & other serious MRSA infections

| #  | Drug  | Dose-form       | Size/strength                      | Level  |
|--|---|-----------------|------------------------------------|--------|
| 6.2.3.1  | Clofazamine   | Capsule         | a) 50mg<br>b) 100mg                | 4<br>4 |
| 6.2.3.2  | Dapsone   | Tablet          | 25mg                               | 4      |
| 6.2.3.3  | Rifampicin  | Capsule/Tablet  | a) 150mg<br>b) 300mg               | 4<br>4 |
| <b>6.2.4 Antituberculosis medicines<sup>48</sup></b> |   |                 |                                    |        |
| <b>Individual drugs</b>                              |   |                 |                                    |        |
| 6.2.4.1  | Ethambutol (E)  | Tablet          | a) 100mg (dispersible)<br>b) 400mg | 2<br>2 |
| 6.2.4.2  | Isoniazid (H)   | Oral liquid     | a) 50mg/5mL [c]                    | 2      |
|  |   | Tablet          | b) 100mg<br>c) 300mg               | 2<br>2 |
| 6.2.4.3  | Pyrazinamide (Z)  | Tablet          | 400mg                              | 2      |
| 6.2.4.4  | Rifampicin (R)  | Capsule         | a) 150mg<br>b) 300mg               | 2<br>2 |
| <b>Fixed-dose combinations (FDCs)</b>                |   |                 |                                    |        |
| 6.2.4.6  | Isoniazid + ethambutol (HE)                               | Tablet          | 150mg + 400mg                      | 2      |
| 6.2.4.7  | Rifampicin + isoniazid (RH)                               | Tablet          | a) 150mg + 75mg                    | 2      |
|  |   |                 | b) 75mg + 50mg [c]                 | 2      |
| 6.2.4.8  | Rifampicin + isoniazid + ethambutol + (RHE)               | Tablet          | 150mg + 75mg + 275mg               | 2      |
| 6.2.4.9  | Rifampicin + isoniazid + pyrazinamide + (RHZ)             | Tablet          | a) 150mg + 75mg + 400mg            | 2      |
|  |   |                 | b) 75mg + 50mg + 150mg [c]         | 2      |
| 6.2.4.10   | Rifampicin + isoniazid + pyrazinamide + ethambutol (RHZE) | Tablet          | 150mg + 75mg + 400mg + 275mg       | 2      |
| <b>Specialist List</b>                               |   |                 |                                    |        |
| 6.2.4.11   | Amikacin  | PFI             | 500mg vial (as sulphate)           |        |
| 6.2.4.12   | Bedaquiline   | Tablet          | 100mg                              |        |
| 6.2.4.13   | Capreomycin   | PFI             | 1g vial (as sulphate)              |        |
| 6.2.4.14   | Cycloserine   | Tablet          | 250mg                              |        |
| 6.2.4.15   | Delamanid   | Tablet          | 50mg                               |        |
| 6.2.4.16   | Kanamycin   | PFI             | 1g vial (as sulphate)              |        |
| 6.2.4.17   | Levofloxacin  | Tablet (scored) | 500mg                              |        |
| 6.2.4.18   | Linezolid   | Tablet          | 600mg                              |        |

<sup>47</sup>Use only in combination, never individually

<sup>48</sup>Antituberculosis treatment must always be with FDCs +/- additional individual drugs

| #   | Drug                                 | Dose-form                   | Size/strength                      | Level  |
|---|--------------------------------------|-----------------------------|------------------------------------|--------|
| 6.2.4.19  | Moxifloxacin                         | Tablet                      | 400mg                              |        |
| 6.2.4.20  | p-aminosalicylic acid (PAS)          | Granules                    | 4g sachet                          |        |
| 6.2.4.21  | Prothionamide                        | Tablet                      | 250mg                              |        |
| 6.2.4.22  | Rifabutin (RFB <sub>3</sub> )        | Capsule                     | 150mg                              |        |
| <b>6.3 Antifungals</b>  |                                      |                             |                                    |        |
| 6.3.1   | Amphotericin B <sup>49</sup>         | PFI                         | 50mg vial (as sodium deoxycholate) | 4      |
| 6.3.2   | Clotrimazole <sup>50</sup>           | Vaginal tablet              | 500mg                              | 2      |
| 6.3.3   | Fluconazole                          | Capsule                     | a) 50mg <sup>51</sup><br>b) 200mg  | 2<br>4 |
|   |                                      | c) Injection <sup>52</sup>  | 2mg/mL<br>(100mL bottle)           | 4      |
|   |                                      | d) Oral liquid [c]          | 50mg/5mL                           | 4      |
|   |                                      | 6.3.4                       | Griseofulvin                       | Tablet |
| 6.3.5   | Nystatin                             | Oral liquid<br>(suspension) | 100,000 IU/mL                      | 2      |
| <b>6.4 Antivirals</b>   |                                      |                             |                                    |        |
| <b>6.4.1 Antiherpes medicines</b>   |                                      |                             |                                    |        |
| 6.4.1.1   | Aciclovir                            | Tablet                      | 200mg (scored)                     | 2      |
| <i>Specialist List</i>  |                                      |                             |                                    |        |
| 6.4.1.2   | Aciclovir <sup>53</sup>              | PFI                         | 250mg vial (as sodium salt)        |        |
| <b>6.4.2 Antiretrovirals</b>  |                                      |                             |                                    |        |
| <b>6.4.2.1 Nucleoside/nucleotide reverse transcriptase inhibitors (NRTI)</b>      |                                      |                             |                                    |        |
| 6.4.2.1.1   | Abacavir (ABC) <sup>54</sup>         | Tablet                      | 300mg                              | 2      |
| 6.4.2.1.2   | Lamivudine (3TC)                     | a) Oral liquid              | 50mg/5mL                           | 2      |
|   |                                      | b) Tablet <sup>55</sup>     | 150mg                              | 2      |
| <b>6.4.2.2 Non-Nucleoside/nucleotide reverse transcriptase inhibitors (NNRTI)</b> |                                      |                             |                                    |        |
| 6.4.2.2.1   | Efavirenz <sup>56</sup> (EFV or EFZ) | Tablet                      | a) 200mg<br>(cross-scored)         | 2      |
|   |                                      |                             | b) 600mg <sup>57</sup>             | 2      |
| 6.4.2.2.2   | Etravirine (ETV) <sup>58</sup>       | Tablet                      | 100mg                              | 4      |

<sup>49</sup> Only use in invasive fungal infections

<sup>50</sup> Use as alternative to fluconazole in pregnancy

<sup>51</sup> Use at Level 2 restricted to STI syndromic management only

<sup>52</sup> Use only in cryptococcal meningitis

<sup>53</sup> Use only in viral encephalitis

<sup>54</sup> Use only in patients >10kg

<sup>55</sup> Use only in patients >11kg

<sup>56</sup> Use only in patients >3 years or >10kg

<sup>57</sup> Use only in patients ≥40Kg

| #   | Drug   | Dose-form                             | Size/strength                               | Level |
|---|--|---------------------------------------|---|-------|
| 6.4.2.2.2                                     | Nevirapine (NVP)   | a) Oral liquid                        | 10mg/mL                                     | 2     |
|   |  | b) Tablet                             | 200mg                                       | 2     |
| <b>6.4.2.3 Protease inhibitors</b>            |  |                                       |   |       |
| 6.4.2.3.1                                     | Atazanavir + ritonavir <sup>59</sup>                               | Tablet                                | 300mg + 100mg                               | 2     |
| 6.4.2.3.2                                     | Darunavir <sup>60</sup> (TCM)                                      | Tablet, f/c                           | 600mg                                       | 4     |
| 6.4.2.3.3                                     | Lopinavir + ritonavir (LPV/r)                                      | a) Oral liquid                        | 400mg + 100mg/5mL                           | 2     |
|   |  | b) Tablet (heat-stable) <sup>61</sup> | 200mg + 50mg                                | 2     |
| 6.4.2.3.4                                     | Ritonavir  | Oral liquid                           | 400mg/5mL                                   | 2     |
| <b>6.4.2.4 Integrase inhibitor</b>            |  |                                       |   |       |
| 6.4.2.4.1                                     | Raltegravir  | Tablet                                | a) 25mg (chewable) <sup>62</sup>            | 4     |
|   |  |                                       | b) 100mg (chewable) <sup>63</sup>           | 4     |
|   |  |                                       | c) 400mg, f/c <sup>64</sup>                 | 4     |
| <b>6.4.2.5 Fixed-dose combinations (FDCs)</b> |  |                                       |   |       |
| 6.4.2.5.1                                     | Abacavir + lamivudine (ABC + 3TC)                                  | Tablet (dispersible, scored)          | 60mg (as sulphate) + 30mg                   | 2     |
| 6.4.2.5.2                                     | Efavirenz + lamivudine + tenofovir (EFV + 3TC + TDF) <sup>65</sup> | Tablet                                | 600mg + 300mg + 300mg (disoproxil fumarate) | 2     |
| 6.4.2.5.3                                     | Lamivudine + tenofovir (3TC + TDF) <sup>66</sup>                   | Tablet                                | 300mg + 300mg (disoproxil fumarate)         | 2     |
| 6.4.2.5.4                                     | Lamivudine + zidovudine (3TC + ZDV)                                | Tablet                                | a) 30mg + 60mg                              | 2     |
|   |  |                                       | b) 150mg + 300mg <sup>67</sup>              | 2     |
| 6.4.2.5.5                                     | Lamivudine + nevirapine + zidovudine (3TC + NVP + ZDV)             | Tablet                                | a) 30mg + 50mg + 60mg                       | 2     |
|   |  |                                       | b) 150mg + 200mg +                          | 2     |

<sup>58</sup> Use only in patients >6 years and >16kg

<sup>59</sup> Use only in patients ≥40Kg

<sup>60</sup> Use only in patients ≥40Kg

<sup>61</sup> Use only in patients >12kg

<sup>62</sup> Use only in patients >11kg

<sup>63</sup> Use only in patients >14kg

<sup>64</sup> Use only in patients >12 years old

<sup>65</sup> Use only in patients of ≥12 years and ≥40kg

<sup>66</sup> Use only in patients of ≥12 years and ≥35kg

<sup>67</sup> Use only in patients >14kg

| #   | Drug                                   | Dose-form                                | Size/strength                         | Level |
|---|--|--|---------------------------------------|-------|
|   |  |  | 300mg <sup>68</sup>                   |       |
| <b>6.4.3 Other antivirals</b>                         |  |  |                                       |       |
| <i>Specialist List</i>                                |  |  |                                       |       |
| 6.4.3.1   | Ganciclovir <sup>69</sup>              | PFI                                      | 500mg vial                            |       |
| 6.4.3.2   | Ribavirin <sup>70</sup>                | Tablet<br>(film-coated)                  | a) 200mg<br>b) 400mg                  |       |
| <b>6.4.4 Antihepatitis medicines</b>                  |  |  |                                       |       |
| <b>6.4.4.1 Hepatitis B medicines</b>                  |  |  |                                       |       |
| <i>Specialist List</i>                                |  |  |                                       |       |
| 6.4.4.1.1   | Pegylated interferon<br>alfa-2a        | Injection (vial or<br>prefilled syringe) | 180 micrograms                        |       |
| 6.4.4.1.2   | Tenofovir disoproxil fumarate<br>(TDF) | Tablet                                   | 300mg <sup>71</sup>                   |       |
| <b>6.4.4.2 Hepatitis C medicines</b>                  |  |  |                                       |       |
| <i>Specialist List</i>                                |  |  |                                       |       |
| 6.4.4.2.1   | Pegylated interferon<br>alfa-2a        | Injection (vial or<br>prefilled syringe) | 180 micrograms                        |       |
| 6.4.4.2.2   | Ribavirin <sup>72</sup>                | Tablet<br>(film-coated)                  | a) 200mg<br>b) 400mg                  |       |
| <b>6.5 Antiprotozoals</b>                             |  |  |                                       |       |
| <b>6.5.1 Antiamoebic &amp; anti giardia Medicines</b> |  |  |                                       |       |
| 6.5.1.1   | Diloxanide <sup>73</sup>               | Tablet                                   | 500mg (furoate)                       | 2     |
| 6.5.1.2   | Metronidazole                          | a) Injection                             | 500mg/100mL vial                      | 2     |
|   |  | b) Oral liquid                           | 200mg/5mL (as<br>benzoate)            | 2     |
|   |  | c) Tablet                                | 400mg (scored)                        | 2     |
| 6.5.1.3   | Tinidazole <sup>74</sup>               | Tablet                                   | 500mg                                 | 2     |
| <b>6.5.2 Antileishmaniasis medicines</b>              |  |  |                                       |       |
| 6.5.2.1   | Amphotericin B                         | PFI                                      | 50mg vial (as sodium<br>deoxycholate) | 4     |
| <i>Specialist List</i>                                |  |  |                                       |       |

<sup>68</sup> Use only in patients >14kg

<sup>69</sup> Use in management of cytomegalovirus retinitis (CMV)

<sup>70</sup> Use in treatment of viral haemorrhagic fevers and, in combination with pegylated interferon, in treatment of hepatitis C

<sup>71</sup> TDF equivalent to 245mg tenofovir disoproxil

<sup>72</sup> Use also in treatment of viral haemorrhagic fevers

<sup>73</sup> Use only in patients >25kg

<sup>74</sup> Useful for giardia (2g single dose); may also be used for other indications as a longer acting alternative to metronidazole

| #   | Drug  | Dose-form                             | Size/strength  | Level  |
|---|---|---------------------------------------|--|--------|
| 6.5.2.2   | Paromomycin   | injection solution (IM)               | 375mg base/mL (as sulphate) (2mL amp)                    |        |
| 6.5.2.3   | Sodium stibogluconate                                   | Injection                             | 100mg/mL (100mL amp)                                     |        |
| <b>6.5.3 Antimalarials</b>  |   |                                       |  |        |
| <b>6.5.3.1 Curative</b>   |   |                                       |  |        |
| 6.5.3.1.1   | Artemether + lumefantrine <sup>75</sup> (AL)            | a) Tablet <sup>76</sup>               | 20mg + 120mg   | 1      |
|   |   | b) Tablet (dispersible) <sup>77</sup> | 20mg + 120mg   | 1      |
|   |   | c) Tablet <sup>78</sup>               | 80mg + 480mg   | 1      |
| 6.5.3.1.2   | Artesunate <sup>79</sup>                                | Injection                             | a) 30mg vial <sup>80</sup><br>b) 60mg vial <sup>81</sup> | 3<br>3 |
| 6.5.3.1.3   | Quinine <sup>82</sup> (sulphate or bisulphate)          | Tablet                                | 300mg  | 2      |
| <b>Specialist List</b>  |   |                                       |  |        |
| 6.5.3.1.4   | Dihydroartemisinin + piperazine (DHA+PPQ) <sup>83</sup> | Tablet (scored)                       | 40mg + 320mg   |        |
| <b>6.5.3.2 Prophylactic</b>   |   |                                       |  |        |
| 6.5.3.2.1   | Doxycycline <sup>84</sup>                               | Capsule                               | 100mg (as HCl)   | 2      |
| 6.5.3.2.2   | Proguanil hydrochloride <sup>85</sup>                   | Tablet                                | 100mg  | 4      |
| <b>6.5.3.3 Intermittent presumptive treatment in pregnancy (IPTp)</b> |   |                                       |  |        |
| 6.5.3.3.1   | Sulfadoxine + pyrimethamine                             | Tablet                                | 500mg + 25mg   | 2      |
| <b>6.5.4 Antipneumocystosis and antitoxoplasmosis medicines</b>       |   |                                       |  |        |
| 6.5.4.1   | Cotrimoxazole   | a) Injection                          | 96mg/mL (5mL amp)  | 4      |
|   |   | b) Oral liquid                        | 240mg/5mL [c]  | 4      |

<sup>75</sup>Do not use in 1<sup>st</sup> trimester of pregnancy (use oral quinine)

<sup>76</sup> Use for patients 24-35kg

<sup>77</sup> Use for patients <24kg

<sup>78</sup> Use for patients >35kg

<sup>79</sup> Always follow artesunate treatment (24 hours minimum) with a 3-day course of artemether + lumefantrine (once the patient can take oral medication)

<sup>80</sup>Co-packed with 0.5mL amp of sodium bicarbonate 5% (50mg/mL) and 2.5mL amp of sodium chloride 0.9% (9mg/mL) as diluents

<sup>81</sup>Co-packed with 1mL amp of sodium bicarbonate 5% (50mg/mL) and 5mL amp of sodium chloride 0.9% (9mg/mL) as diluents

<sup>82</sup> Use only for uncomplicated malaria treatment in 1<sup>st</sup> trimester of pregnancy

<sup>83</sup> Use only as 2<sup>nd</sup> line medicine for *confirmed* uncomplicated malaria treatment failure with 1<sup>st</sup> line AL

<sup>84</sup> Use only in patients >8 years; for prophylaxis in non-immune visitors to endemic areas

<sup>85</sup> Use only for prophylaxis in patients with sickle-cell disease and tropical splenomegaly syndrome (TSS)



| #  | Drug                            | Dose-form                                  | Size/strength                        | Level |
|--|---------------------------------|--|--------------------------------------|-------|
|  |                                 | c) Tablet                                  | 480mg                                | 4     |
| 6.5.4.2  | Sulfadoxine + pyrimethamine     | Tablet                                     | 500mg + 25mg                         | 4     |
| <b>6.5.5 Antitrypanosomal medicines</b>          |                                 |  |                                      |       |
| <b>6.5.5.1 African trypanosomiasis</b>           |                                 |  |                                      |       |
| <b>a) Treatment of 1<sup>st</sup> stage</b>      |                                 |  |                                      |       |
| 6.5.5.1.1  | Pentamidine isetionate          | PFI  | 200mg vial                           | 4     |
| <i>Specialist List</i>                           |                                 |  |                                      |       |
| 6.5.5.1.2  | Suramin sodium                  | PFI  | 1g vial                              |       |
| <b>b) Treatment of 2<sup>nd</sup> stage</b>      |                                 |  |                                      |       |
| <i>Specialist List</i>                           |                                 |  |                                      |       |
| 6.5.5.1.3  | Melarsoprol                     | Injection                                  | 3.6% solution (5mL amp)<br>(= 180mg) |       |
| <b>7. ANTIMIGRAINE MEDICINES</b>                 |                                 |  |                                      |       |
| <b>7.1 Acute attack</b>                          |                                 |  |                                      |       |
| 7.1.1  | Aspirin                         | Tablet                                     | 300mg                                | 2     |
| 7.1.2  | Ibuprofen <sup>86</sup>         | Tablet                                     | 200mg                                | 2     |
| 7.1.3  | Paracetamol                     | a) Oral liquid [c]                         | 125mg/5mL <sup>87</sup>              | 1     |
|  |                                 | b) Suppository [c]                         | 125mg                                | 1     |
|  |                                 | c) Tablet (scored)                         | 500mg                                | 1     |
| <b>7.2 Prophylactics</b>                         |                                 |  |                                      |       |
| 7.2.1  | PropranololHCl <sup>88</sup>    | Tablet                                     | 40mg                                 | 4     |
| <b>8. ANTINEOPLASTICS and IMMUNOSUPPRESSIVES</b> |                                 |  |                                      |       |
| <b>8.1 Immunosuppressives</b>                    |                                 |  |                                      |       |
| <i>Specialist List</i>                           |                                 |  |                                      |       |
| 8.1.1  | Azathioprine                    | a) PFI                                     | 100mg vial (sodium salt)             |       |
|  |                                 | b) Tablet (scored)                         | 50mg                                 |       |
| 8.1.2  | Ciclosporin                     | a) Capsule                                 | 25mg                                 |       |
|  |                                 | b) Concentrate for injection <sup>89</sup> | 50mg/1mL amp                         |       |
| 8.1.3  | Methylprednisolone              | PFI (as sod. succinate)                    | a) 125mg<br>b) 500mg                 |       |
| 8.1.4  | Mycophenolic acid <sup>90</sup> | Tablet (e/c)                               | a) 180mg                             |       |

<sup>86</sup> Do not use in children < 3 months old

<sup>87</sup> 120mg/5mL is an alternative strength

<sup>88</sup> Use only for this indication (ie. do **not** use as an alternative antihypertensive)

<sup>89</sup> Use in organ transplantation

| #                                   | Drug                                    | Dose-form                                 | Size/strength  | Level |
|-------------------------------------|---|---|--|-------|
| 8.1.5                               | (as mycophenolate sod.)<br>Prednisolone | Tablet                                    | b) 360mg<br>5mg                                      |       |
| 8.1.6                               | Tacrolimus                              | a) Concentrate for IV infusion<br>Capsule | 5mg/1mL amp<br>b) 500 micrograms<br>c) 1mg<br>d) 5mg |       |
| <b>8.2 Cytotoxics and adjuvants</b> |   |   |  |       |
| <i>Specialist List</i>              |   |   |  |       |
| 8.2.1                               | Alendronic acid <sup>91</sup>           | Tablet                                    | 70mg   |       |
| 8.2.2                               | Allopurinol <sup>92</sup>               | Tablet                                    | a) 100mg<br>b) 300mg                                 |       |
| 8.2.3                               | Asparaginase <sup>93</sup>              | PFI                                       | 10,000 IU vial                                       |       |
| 8.2.4                               | Bleomycin <sup>94</sup>                 | PFI                                       | 15mg vial (as sulphate)                              |       |
| 8.2.5                               | Calcium folinate <sup>95</sup>          | Injection                                 | a) 10mg/mL (5mL vial)                                |       |
|                                     |   | Tablet                                    | b) 15mg  |       |
| 8.2.6                               | Capecitabine <sup>96</sup>              | Tablet                                    | a) 150mg   |       |
|                                     |   |   | b) 500mg   |       |
| 8.2.7                               | Carboplatin <sup>97</sup>               | Injection                                 | a) 10mg/mL (15mL vial)                               |       |
|                                     |   |   | b) 10mg/mL (45mL vial)                               |       |
| 8.2.8                               | Chlorambucil <sup>98</sup>              | Tablet                                    | 2mg  |       |
| 8.2.9                               | Cisplatin <sup>99</sup>                 | Injection                                 | 1mg/mL (50mL vial)                                   |       |
| 8.2.10                              | Cyclophosphamide <sup>100</sup>         | PFI                                       | a) 200mg vial  |       |

<sup>90</sup> Mycophenolate mofetil tablets 250mg & 500mg may be available as a much cheaper alternative but with a less favourable side-effects profile; the two salts are not interchangeable as they have different pharmacokinetics

<sup>91</sup> Use as adjuvant in management of breast & prostate cancers and multiple myeloma

<sup>92</sup> Use for prophylaxis of chemotherapy-induced hyperuricaemia

<sup>93</sup> Use in acute lymphoblastic leukemia; anaphylaxis treatment must be available; the type required is that produced by *Erwinia chrysanthemi* (also known as crisantaspase)

<sup>94</sup> Use in Hodgkin lymphoma, Kaposi sarcoma, ovarian and testicular germ cell tumour

<sup>95</sup> Use in early stage colon & rectal cancers, gestational trophoblastic neoplasia, metastatic colorectal cancer, osteosarcoma, Burkitt lymphoma; also useful in gynaecological tumours

<sup>96</sup> Use in early stage colon & rectal cancers, metastatic breast & colorectal cancers

<sup>97</sup> Use in early stage breast cancer, epithelial ovarian cancer, nasopharyngeal cancer, non-small cell lung cancer, osteosarcoma, retinoblastoma

<sup>98</sup> Use in chronic lymphocytic leukemia

<sup>99</sup> Use in cervical, head & nasopharyngeal cancers - as a radio-sensitizer; non-small cell lung cancer, osteosarcoma, ovarian & testicular germ cell tumours

| #      | Drug                            | Dose-form                        | Size/strength                                      | Level |
|--------|---------------------------------|----------------------------------|--|-------|
|        |                                 |                                  | b) 500mg vial                                      |       |
|        |                                 | c) Tablet                        | 25mg   |       |
| 8.2.11 | Cytarabine <sup>101</sup>       | PFI                              | 100mg vial   |       |
| 8.2.12 | Dacarbazine <sup>102</sup>      | PFI                              | 200mg vial (as citrate)                            |       |
| 8.2.13 | Dactinomycin <sup>103</sup>     | PFI                              | 500 micrograms vial                                |       |
| 8.2.14 | Daunorubicin <sup>104</sup>     | PFI                              | 20mg vial (as HCl)                                 |       |
| 8.2.15 | Docetaxel <sup>105</sup>        | Injection                        | a) 10mg/mL (2mL vial)<br>b) 10mg/mL (8mL vial)     |       |
| 8.2.16 | Doxorubicin <sup>106</sup>      | PFI                              | a) 10mg vial (as HCl)<br>b) 50mg vial (as HCl)     |       |
| 8.2.17 | Etoposide <sup>107</sup>        | Injection                        | 20mg/mL (5mL vial)                                 |       |
| 8.2.18 | Filgrastim <sup>108</sup>       | Injection<br>(prefilled syringe) | a) 120 micrograms/0.2mL<br>b) 300 micrograms/0.5mL |       |
| 8.2.19 | Fluorouracil <sup>109</sup>     | Injection                        | 50mg/mL (5mL vial)                                 |       |
| 8.2.20 | Gemcitabine <sup>110</sup>      | PFI                              | a) 200mg vial<br>b) 1g vial                        |       |
| 8.2.21 | Hydroxycarbamide <sup>111</sup> | Capsule                          | a) 250mg   |       |

<sup>100</sup> Use in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, early stage breast cancer, gestational trophoblastic neoplasia, Hodgkin & follicular lymphomas, rhabdomyosarcoma, Ewing sarcoma, acute lymphoblastic leukemia, Burkitt lymphoma, metastatic breast cancer

<sup>101</sup> Use in acute myelogenous, lymphoblastic & promyelocytic leukemias, Burkitt lymphoma

<sup>102</sup> Use in Hodgkin lymphoma

<sup>103</sup> Use in gestational trophoblastic neoplasia, rhabdomyosarcoma, Wilms tumour

<sup>104</sup> Use in acute myelogenous & promyelocytic leukemias

<sup>105</sup> Use in early stage & metastatic breast cancers, metastatic prostate cancer

<sup>106</sup> Use in diffuse large B-cell lymphoma, early stage breast cancer, Hodgkin lymphoma, Kaposi sarcoma, follicular lymphoma, metastatic breast cancer, osteosarcoma, Ewing sarcoma, acute lymphoblastic leukemia, Wilms tumour, Burkitt lymphoma

<sup>107</sup> Use in testicular germ cell tumour, gestational trophoblastic neoplasia, Hodgkin and Burkitt lymphomas, non-small cell lung cancer, ovarian germ cell tumour, retinoblastoma, Ewing sarcoma, acute lymphoblastic leukemia

<sup>108</sup> Use as primary prophylaxis in those at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy; use as secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy, to facilitate administration of dose dense chemotherapy regimens

<sup>109</sup> Use in early stage breast, colon & rectal cancers, metastatic colorectal cancer, nasopharyngeal cancer

<sup>110</sup> Use in epithelial ovarian cancer, non-small cell lung cancer

| #      | Drug                          | Dose-form  | Size/strength  | Level |
|--------|-------------------------------|--|--|-------|
|        | (hydroxyurea)                 |  | b) 500mg   |       |
| 8.2.22 | Ifosfamide <sup>112</sup>     | PFI  | a) 1g vial<br>b) 2g vial   |       |
| 8.2.23 | Imatinib <sup>113</sup>       | Tablet (as mesilate)                                     | 400mg  |       |
| 8.2.24 | Irinotecan <sup>114</sup>     | Injection  | a) 20mg/mL (2mL vial)<br>b) 20mg/mL (5mL vial)   |       |
| 8.2.25 | Mercaptopurine <sup>115</sup> | Tablet   | 50mg   |       |
| 8.2.26 | Melphalan <sup>116</sup>      | Tablet   | 2mg  |       |
| 8.2.27 | Mesna <sup>117</sup>          | Injection (solution for infusion)                        | 100mg/mL (2mL amp)   |       |
| 8.2.28 | Methotrexate <sup>118</sup>   | PFI (as sodium salt)<br>(preservative-free)<br>c) Tablet | a) 25mg/mL (2mL vial)<br>b) 25mg/mL (20mL vial) <sup>119</sup><br>2.5mg (as sodium salt) |       |
| 8.2.29 | Oxaliplatin <sup>120</sup>    | Injection  | 5mg/mL (10mL vial)   |       |
| 8.2.30 | Paclitaxel <sup>121</sup>     | Concentrate (for IV infusion)                            | a) 6mg/mL (5mL vial)<br>b) 6mg/mL (16.7mL vial) <sup>122</sup>                           |       |
| 8.2.31 | Procarbazine                  | Capsule  | 50mg (as HCl)  |       |
| 8.2.32 | Rituximab <sup>123</sup>      | Injection  | a) 10mg/mL (10mL vial)<br>b) 10mg/mL (50mL vial)   |       |
| 8.2.33 | Thalidomide <sup>124</sup>    | Capsule  | 100mg  |       |

<sup>111</sup>Use in chronic myeloid leukemia

<sup>112</sup>Use in testicular & ovarian germ cell tumour, osteosarcoma, rhabdomyosarcoma, Ewing sarcoma

<sup>113</sup>Use in chronic myeloid leukemia, gastrointestinal stromal tumour

<sup>114</sup>Use as 2<sup>nd</sup> line agent in metastatic colorectal cancer

<sup>115</sup>Use in acute lymphoblastic & promyelocytic leukemias

<sup>116</sup>Use in multiple myeloma

<sup>117</sup>Use in testicular & ovarian germ cell tumours, osteosarcoma, rhabdomyosarcoma, Ewing sarcoma

<sup>118</sup>Use in early stage breast cancer, gestational trophoblastic neoplasia, osteosarcoma, acute lymphoblastic and promyelocytic leukaemias

<sup>119</sup>Providing a total of 500mg per 20mL vial

<sup>120</sup>Use in early stage colon cancer, metastatic colorectal cancer

<sup>121</sup>Use in epithelial ovarian cancer, early stage & metastatic breast cancers, Kaposi sarcoma, nasopharyngeal cancer, non-small cell lung cancer, ovarian germ cell tumour

<sup>122</sup>Providing a total of 100mg/vial

<sup>123</sup>Use in diffuse large B-cell and follicular lymphomas, chronic lymphocytic leukemia

| #                                    | Drug                                  | Dose-form                       | Size/strength                                   | Level |
|--------------------------------------|---------------------------------------|---------------------------------|---|-------|
| 8.2.34                               | Trastuzumab <sup>125</sup>            | PFI                             | a) 150mg vial<br>b) 440mg vial + diluent        |       |
| 8.2.35                               | Vinblastine sulphate <sup>126</sup>   | Injection                       | 1mg/mL (10mL vial)                              |       |
| 8.2.36                               | Vinorelbine <sup>127</sup>            | Injection                       | a) 10mg/mL (1mL vial)<br>b) 10mg/mL (5mL vial)  |       |
| 8.2.37                               | Zoledronic acid <sup>128</sup>        | Injection                       | 800 micrograms/mL (5mL vial) <sup>129</sup>     |       |
| <b>8.3 Hormones and antihormones</b> |                                       |                                 |   |       |
| <i>Specialist List</i>               |                                       |                                 |   |       |
| 8.3.1                                | Anastrozole <sup>130</sup>            | Tablet                          | 1mg   |       |
| 8.3.2                                | Bicalutamide <sup>131</sup>           | Tablet                          | 50mg  |       |
| 8.3.3                                | Dexamethasone <sup>132</sup>          | a) Injection                    | 4mg/1mL amp (as sodium phosphate)               |       |
|                                      |                                       | b) Tablet                       | 500 micrograms                                  |       |
| 8.3.4                                | Diethylstilboestrol (DES)             | Tablet                          | 5mg   |       |
| 8.3.5                                | Goserelin <sup>133</sup>              | Implant (in syringe applicator) | a) 3.6mg (as acetate)<br>b) 10.8mg (as acetate) |       |
|                                      |                                       |                                 |   |       |
| 8.3.6                                | Hydroxycortisone <sup>134</sup>       | PFI                             | 100mg vial (as sodium succinate)                |       |
| 8.3.7                                | Methylprednisolone <sup>135</sup> [c] | PFI                             | 500mg vial                                      |       |
| 8.3.8                                | Prednisolone <sup>136</sup>           | a) Oral liquid [c]              | 15mg/5mL  |       |
|                                      |                                       | Tablet                          | b) 5mg<br>c) 25mg                               |       |
| 8.3.9                                | Tamoxifen <sup>137</sup>              | Tablet                          | 20mg (as citrate)                               |       |

<sup>124</sup> Use (with melphalan & prednisolone) in management of multiple myeloma

<sup>125</sup> Use in early stage & metastatic HER2-positive breast cancer

<sup>126</sup> Use in Hodgkin lymphoma, Kaposi sarcoma, testicular & ovarian germ cell tumour

<sup>127</sup> Use in non-small cell lung cancer, metastatic breast cancer

<sup>128</sup> Use as adjuvant in management of breast & prostate cancers and multiple myeloma

<sup>129</sup> Provides a total of 4mg per vial

<sup>130</sup> Letrozole tablets 2.5mg may be available and used as a much cheaper alternative

<sup>131</sup> Use in metastatic prostate cancer

<sup>132</sup> Use in acute lymphoblastic leukemia

<sup>133</sup> Use in early stage & metastatic breast cancers; leuprorelin may be available and used as an alternative

<sup>134</sup> Use in acute lymphoblastic leukemia

<sup>135</sup> Use in acute lymphoblastic leukemia

<sup>136</sup> Use in chronic lymphocytic & acute lymphoblastic leukemias; diffuse large B-cell, Hodgkin, follicular & Burkitt lymphomas

| #   | Drug                            | Dose-form              | Size/strength                                    | Level |
|---|---------------------------------|------------------------|--|-------|
| <b>8.4 Medicines for benign prostatic hyperplasia (BPH)</b> |                                 |                        |  |       |
| <i>Specialist List</i>                                      |                                 |                        |  |       |
| 8.4.1   | Finasteride                     | Tablet                 | 5mg  |       |
| 8.4.2   | Tamsulosin HCL                  | Tablet                 | 400 micrograms                                   |       |
| <b>9. ANTIPARKINSONISM MEDICINES</b>                        |                                 |                        |  |       |
| 9.1   | BenzhexolHCl                    | Tablet                 | 5mg  | 4     |
| 9.2   | Levodopa + carbidopa            | Tablet                 | a) 100mg + 10mg                                  | 4     |
|   |                                 |                        | b) 250mg + 25mg                                  | 4     |
| <i>Specialist List</i>                                      |                                 |                        |  |       |
| 9.3   | Pramipexole                     | Tablet (scored)        | a) 180 micrograms base<br>b) 700 micrograms base |       |
| <b>10. MEDICINES AFFECTING the BLOOD</b>                    |                                 |                        |  |       |
| <b>10.1 Antianaemics</b>                                    |                                 |                        |  |       |
| 10.1.1  | Ferrous salt                    | a) Oral liquid (drops) | 25mg/mL elemental iron <sup>138</sup>            | 2     |
|   |                                 | b) Tablet              | 60-65mg elemental iron <sup>139</sup>            | 2     |
| 10.1.2  | Ferrous salt + folic acid       | Tablet                 | 60-65mg elem. iron + 400 micrograms              | 2     |
| 10.1.3  | Folic acid                      | Tablet                 | a) 400 micrograms <sup>140</sup>                 | 2     |
|   |                                 |                        | b) 5mg   | 4     |
| 10.1.4  | Hydroxocobalamin <sup>141</sup> | Injection              | 1mg/1mL amp (as HCl, acetate or sulphate)        | 4     |
| <b>10.2 Medicines affecting coagulation</b>                 |                                 |                        |  |       |
| 10.2.1  | Heparin sodium                  | Injection              | 5,000 IU/mL (5mL vial)                           | 4     |
| 10.2.2  | Phytomenadione (Vit K1)         | Injection              | a) 1mg/1mL amp [c]                               | 2     |
|   |                                 |                        | b) 10mg/mL (5mL amp)                             | 4     |
| 10.2.3  | Protamine sulphate              | Injection              | 10mg/mL (5mL amp)                                | 4     |
| 10.2.4  | Tranexamic acid                 | Injection              | 100mg/mL (5mL amp)                               | 4     |
| 10.2.5  | Warfarin sodium                 | Tablet                 | a) 1mg   | 4     |

<sup>137</sup> Use in early stage & metastatic breast cancers

<sup>138</sup> Eg. ferrous sulphate solution 125mg/mL

<sup>139</sup> Eg. dried ferrous sulphate tablets 200mg

<sup>140</sup> Use periconceptually for prevention of first occurrence of neural tube defects

<sup>141</sup> Use cyanocobalamin tablet 1mg as the preferred alternative (if available)

| #  | Drug                            | Dose-form                        | Size/strength                                     | Level  |
|--|---------------------------------|----------------------------------|---|--------|
|  |                                 |                                  | b) 2mg<br>c) 5mg                                  | 4<br>4 |
| <b>Specialist List</b>   |                                 |                                  |   |        |
| 10.2.6   | Enoxaparin                      | Injection<br>(prefilled syringe) | a) 40mg/0.4mL<br>b) 80mg/0.8mL                    |        |
| 10.2.7   | Heparin sodium [c]              | Injection                        | 5,000 IU/mL (5mL vial)                            |        |
| 10.2.8   | Protamine sulphate [c]          | Injection                        | 10mg/mL (5mL amp)                                 |        |
| 10.2.9   | Warfarin sodium [c]             | Tablet                           | a) 0.5mg<br>b) 1mg<br>c) 2mg<br>d) 5mg            |        |
| <b>10.3 Other medicines for haemaglobinopathies</b>              |                                 |                                  |   |        |
| <b>Specialist List</b>   |                                 |                                  |   |        |
| 10.3.1   | Deferasirox                     | Tablet                           | 500mg   |        |
| 10.3.2   | Deferoxaminemesilate            | PFI                              | 500mg vial  |        |
| 10.3.3   | Hydroxycarbamide <sup>142</sup> | Capsule                          | a) 250mg<br>b) 500mg                              |        |
| <b>11. BLOOD PRODUCTS of HUMAN ORIGIN and PLASMA SUBSTITUTES</b> |                                 |                                  |   |        |
| <b>11.1 Blood and blood components</b>                           |                                 |                                  |   |        |
| 11.1.1   | Plasma, fresh frozen            |                                  |   | 4      |
| 11.1.2   | Platelets                       |                                  |   | 4      |
| 11.1.3   | Red blood cells                 |                                  |   | 4      |
| 11.1.4   | Whole blood                     |                                  |   | 4      |
| <b>11.2 Plasma-derived medicines</b>                             |                                 |                                  |   |        |
| <b>11.2.1 Human immunoglobulins (Ig)</b>                         |                                 |                                  |   |        |
| 11.2.1.1   | Anti-D Ig (human)               | Injection                        | 250 micrograms<br>vial <sup>143</sup>             | 4      |
| 11.2.1.2   | Anti-rabies Ig (equine)         | Injection                        | 200 IU/mL (5mL vial)                              | 2      |
| 11.2.1.3   | Anti-tetanus Ig (human)         | Injection                        | 500 IU vial                                       | 4      |
| <b>Specialist List</b>   |                                 |                                  |   |        |
| 11.2.1.4   | Normal Ig <sup>144</sup>        | Injection (IV)<br>(100mL vial)   | a) 5% protein solution<br>b) 10% protein solution |        |
| <b>11.2.2 Blood coagulation factors</b>                          |                                 |                                  |   |        |
| <b>Specialist List</b>   |                                 |                                  |   |        |
| 11.2.2.1   | Coagulation factor VIII         | PFI                              | 500 IU vial                                       |        |
| 11.2.2.2   | Coagulation factor IX           | PFI                              | 500 IU vial                                       |        |

<sup>142</sup> Previously called hydroxyurea; use in management of sickle-cell disease

<sup>143</sup> Single-dose

<sup>144</sup> Use for primary immune deficiency and Kawasaki disease

| #                                   | Drug                                    | Dose-form              | Size/strength  | Level  |
|-------------------------------------|---|------------------------|--|--------|
| <b>11.3 Plasma substitutes</b>      |   |                        |  |        |
| 11.3.1                              | Polygeline <sup>145</sup>               | IV infusion            | 3.5% (500mL pack)                                      | 4      |
| <b>12. CARDIOVASCULAR MEDICINES</b> |   |                        |  |        |
| <b>12.1 Antianginals</b>            |   |                        |  |        |
| 12.1.1                              | Carvedilol                              | Tablet                 | a) 6.25mg  | 4      |
|                                     |   |                        | b) 12.5mg  | 4      |
| 12.1.2                              | Glyceryl trinitrate                     | Tablet<br>(sublingual) | 500 micrograms   | 4      |
| 12.1.3                              | Isosorbide dinitrate                    | Tablet                 | 20mg   | 4      |
| <b>12.2 Antiarrhythmics</b>         |   |                        |  |        |
| 12.2.1                              | Carvedilol                              | Tablet                 | a) 6.25mg  | 4      |
|                                     |   |                        | b) 12.5mg  | 4      |
| 12.2.2                              | Digoxin                                 | Oral liquid            | 50 micrograms/mL                                       | 4      |
|                                     |   | Tablet                 | a) 62.5 micrograms<br>b) 250 micrograms                | 4<br>4 |
| 12.2.3                              | LidocaineHCl <sup>146</sup>             | Injection              | 20mg/mL (5mL amp)                                      | 4      |
| 12.2.4                              | VerapamilHCl                            | Injection              | a) 2.5mg/mL<br>(2mL amp)                               | 4      |
|                                     |   | Tablet                 | b) 80mg (scored)                                       | 4      |
| <b>Specialist List</b>              |   |                        |  |        |
| 12.2.5                              | AmiodaroneHCl <sup>147</sup>            | Injection              | 50mg/mL (3mL amp)                                      | 4      |
| 12.2.6                              | Epinephrine (adrenaline) <sup>148</sup> | Injection              | 100 micrograms/mL (10mL amp) (as HCl or acid tartrate) | 4      |
| <b>12.3 Antihypertensives</b>       |   |                        |  |        |
| 12.3.1                              | Amlodipine <sup>149</sup>               | Tablet                 | 5mg  | 4      |
| 12.3.2                              | Carvedilol                              | Tablet                 | a) 6.25mg  | 4      |
|                                     |   |                        | b) 12.5mg  | 4      |
| 12.3.3                              | Enalapril                               | Tablet                 | 5mg (scored) <sup>150</sup>                            | 4      |
| 12.3.4                              | HydralazineHCl                          | PFI                    | a) 20mg  | 4      |
|                                     |   | Tablet                 | b) 25mg  | 4      |

<sup>145</sup> Partially degraded gelatin

<sup>146</sup> Only for IV use in ICU

<sup>147</sup> Only for IV use in ICU

<sup>148</sup>\*Alert\* Note the strength and presentation for this indication - equivalent to 0.01% or 1 in 10,000 - this is 1/10 of the strength of the other form of epinephrine (adrenaline) listed elsewhere; must be diluted for paediatric use

<sup>149</sup> As besylate, maleate or mesylate

<sup>150</sup> As hydrogen maleate



| #   | Drug                                | Dose-form          | Size/strength                           | Level  |
|---|-------------------------------------|--------------------|---|--------|
| 12.3.5                                      | Hydrochlorothiazide                 | Tablet (scored)    | 25mg                                    | 4      |
| 12.3.6                                      | Losartan                            | Tablet             | 50mg                                    | 4      |
| 12.3.7                                      | Methyldopa <sup>151</sup>           | Tablet             | 250mg                                   | 4      |
| <b>Specialist List</b>                      |                                     |                    |   |        |
| 12.3.8                                      | Sodium nitroprusside                | PFI                | 50mg ampoule                            |        |
| <b>12.4 Medicines used in heart failure</b> |                                     |                    |   |        |
| 12.4.1                                      | Carvedilol                          | Tablet             | a) 6.25mg                               | 4      |
|   |                                     |                    | b) 12.5mg                               | 4      |
| 12.4.2                                      | Digoxin                             | Oral liquid        | 50 micrograms/mL                        | 4      |
|   |                                     | Tablet             | a) 62.5 micrograms<br>b) 250 micrograms | 4<br>4 |
| 12.4.3                                      | Furosemide                          | a) Injection       | 10mg/mL (2mL amp)                       | 4      |
|   |                                     | b) Oral liquid [c] | 20mg/5mL                                | 4      |
|   |                                     | c) Tablet (scored) | 40mg                                    | 4      |
| 12.4.4                                      | Hydrochlorothiazide                 | Tablet (scored)    | 25mg                                    | 4      |
| 12.4.5                                      | Spirolonactone                      | Tablet (scored)    | 25mg                                    | 4      |
| <b>Specialist List</b>                      |                                     |                    |   |        |
| 12.4.6                                      | DopamineHCl <sup>152</sup>          | Injection          | 40mg/mL (5mL vial)                      |        |
| <b>12.5 Antithrombotics<sup>153</sup></b>   |                                     |                    |   |        |
| <b>12.5.1 Antiplatelets</b>                 |                                     |                    |   |        |
| 12.5.1.1                                    | Aspirin                             | Tablet             | 75mg                                    | 4      |
| <b>Specialist List</b>                      |                                     |                    |   |        |
| 12.5.1.2                                    | Clopidogrel                         | Tablet             | 25mg                                    |        |
| <b>12.6 Lipid-lowering agents</b>           |                                     |                    |   |        |
| 12.6.1                                      | Atorvastatin <sup>154</sup>         | Tablet (scored)    | 20mg                                    | 4      |
| <b>13. DERMATOLOGICALS (topical)</b>        |                                     |                    |   |        |
| <b>13.1 Antifungals</b>                     |                                     |                    |   |        |
| 13.1.1                                      | Clotrimazole                        | Cream              | 1% (15g)                                | 1      |
| 13.1.2                                      | TerbinafineHCl <sup>155</sup>       | Cream              | 1% (15g)                                | 4      |
| <b>13.2 Anti-infectives</b>                 |                                     |                    |   |        |
| 13.2.1                                      | Fusidic acid <sup>156</sup>         | Ointment           | 2% (15g)                                | 4      |
| 13.2.2                                      | Silver sulphadiazine <sup>157</sup> | Cream              | 1% (250g)                               | 2      |

<sup>151</sup> Only use for hypertension in pregnancy

<sup>152</sup> Only for use in ICU

<sup>153</sup> See also Section 10.2 Medicines affecting coagulation

<sup>154</sup> Use only in high-risk patients; simvastatin may be used as an alternative

<sup>155</sup> Use reserved for in refractive infections

<sup>156</sup> Use restricted to <10 days; sodium fusidate cream 2% may also be available/used

<sup>157</sup> Use only in patients >2mths

| #  | Drug                                | Dose-form                      | Size/strength                   | Level |
|--|-------------------------------------|--------------------------------|---------------------------------|-------|
| <b>Specialist List</b>   |                                     |                                |                                 |       |
| 13.2.3   | Mupirocin <sup>158</sup>            | Cream                          | 2% (15g)                        |       |
| <b>13.3 Anti-inflammatories and antipruritics</b>                        |                                     |                                |                                 |       |
| 13.3.1   | Betamethasone <sup>159</sup>        | Cream                          | 0.1% (15g) (as valerate)        | 4     |
| 13.3.2   | Crotamiton                          | Cream                          | 10% (30g)                       | 2     |
| 13.3.3   | Desonide                            | Gel                            | 0.05% (60g)                     | 2     |
| 13.3.4   | Hydrocortisone acetate              | Ointment                       | 1% (15g)                        | 2     |
| 13.3.5   | Mometasonefuroate                   | Ointment                       | 0.1% (30g)                      | 3     |
| <b>Specialist List</b>   |                                     |                                |                                 |       |
| 13.3.2   | Clobetasone butyrate                | Ointment                       | 0.05% (30g)                     |       |
| 13.3.7   | Tacrolimus (as monohydrate)         | Ointment                       | a) 0.03% (30g)<br>b) 0.1% (30g) |       |
| <b>13.4 Astringents</b>  |                                     |                                |                                 |       |
| None selected  |                                     |                                |                                 |       |
| <b>13.5 Medicines affecting skin differentiation &amp; proliferation</b> |                                     |                                |                                 |       |
| 13.5.1   | Benzoyl peroxide                    | Gel                            | 5% (30g)                        | 3     |
| 13.5.2   | Coal tar + salicylic acid           | Ointment                       | 2% + 2% (100g)                  | 4     |
| 13.5.3   | Podophyllum resin                   | Solution (in benzoin tincture) | 15% (15mL)                      | 4     |
| <b>13.6 Scabics and pediculocides</b>                                    |                                     |                                |                                 |       |
| 13.6.1   | Benzyl benzoate                     | Lotion                         | 25% (50mL)                      | 2     |
| 13.6.2   | Crotamiton                          | Cream                          | 10% (30g)                       | 2     |
| 13.6.3   | Ivermectin                          | Tablet (scored)                | 6mg                             | 4     |
| <b>13.7 Medicines for jiggers<sup>160</sup></b>                          |                                     |                                |                                 |       |
| 13.7.1   | Benzyl benzoate                     | Lotion                         | 25% (50mL)                      | 2     |
| 13.7.2   | White soft paraffin <sup>161</sup>  | Topical application            | 100%                            | 2     |
| <b>13.8 Sunscreen preparation</b>  |                                     |                                |                                 |       |
| 13.8.1   | Sunscreening agent/s <sup>162</sup> | Cream or lotion                | UVB-SPF 30+                     | 3     |
| <b>14. DIAGNOSTIC AGENTS</b>   |                                     |                                |                                 |       |
| <b>14.1 Ophthalmic diagnostics</b>                                       |                                     |                                |                                 |       |
| 14.1.1   | Fluorescein                         | Test strip                     | 0.6mg                           | 4     |
| 14.1.2   | Tropicamide                         | Eye drops                      | 1%                              | 4     |

<sup>158</sup> Use restricted to prevention of infection in dialysis procedures

<sup>159</sup> Avoid use in neonates (hydrocortisone cream preferred)

<sup>160</sup> Tungapenetrans infestation

<sup>161</sup> Also called petroleum jelly or white petrolatum

<sup>162</sup> Must protect against both UVA and UVB; various preparations may be available

| #   | Drug                    | Dose-form                            | Size/strength                                     | Level |
|---|-------------------------|--------------------------------------|---|-------|
| <b>14.2 Radiocontrast media<sup>163</sup></b> |                         |                                      |   |       |
| <i>Specialist List</i>                        |                         |                                      |   |       |
| 14.2.1  | Amidotrizoate           | Injection (solution for IV infusion) | 140-420mg iodine/mL (as sodium or meglumine salt) |       |
| 14.2.2  | Barium sulphate         | Suspension (aq)                      | 20-200%   |       |
| 14.2.3  | Iohexol                 | Injection (solution for IV infusion) | 140-350mg iodine/mL                               |       |
| 14.2.4  | Iopromide               | Injection (solution for IV infusion) | 150-370mg iodine/mL                               |       |
| 14.2.5  | Meglumineiotroxate      | Injection (solution for IV infusion) | 5g iodine in 100mL bottle <sup>164</sup>          |       |
| <b>14.3 MRI contrast media<sup>165</sup></b>  |                         |                                      |   |       |
| <i>Specialist List</i>                        |                         |                                      |   |       |
| 14.3.1  | Gadobutrol              | IV injection (solution)              | 1 mmol/mL <sup>166</sup>                          |       |
| 14.3.2  | Gadodiamide             | IV injection (solution)              | 0.5 mmol/mL <sup>167</sup>                        |       |
| 14.3.3  | Gadopentatedimeglumine  | IV injection (solution)              | 0.5 mmol/mL <sup>168</sup>                        |       |
| <b>15. ANTISEPTICS and DISINFECTANTS</b>      |                         |                                      |   |       |
| <b>15.1 Antiseptics</b>                       |                         |                                      |   |       |
| 15.1.1  | Chlorhexidine           | a) Solution for dilution             | 5% (digluconate)                                  | 2     |
|   |                         | b) Gel [c] <sup>169</sup>            | 4% (as digluconate 7.1%)                          | 3     |
| 15.1.2  | Ethanol                 | Solution                             | 70% (denatured)                                   | 2     |
| 15.1.3  | Povidone iodine         | Solution                             | 10% (equiv. to iodine 1%)                         | 4     |
| <b>15.2 Disinfectants</b>                     |                         |                                      |   |       |
| 15.2.1  | Alcohol-based hand rub  | Solution                             | Isopropyl alcohol 75% (500mL dispenser)           | 1     |
| 15.2.2  | Glutaral <sup>170</sup> | Solution                             | 2%  | 2     |

<sup>163</sup> Required presentations to be selected by the radiologist

<sup>164</sup> Equivalent to 105mg/mL

<sup>165</sup> Required presentations to be selected by the radiologist

<sup>166</sup> Equivalent to 604.72mg/mL

<sup>167</sup> Equivalent to 287mg/mL

<sup>168</sup> Equivalent to 469.01mg/mL

<sup>169</sup> Use only for umbilical cord care

| #  | Drug                             | Dose-form                         | Size/strength                     | Level |
|--|----------------------------------|-----------------------------------|-----------------------------------|-------|
| 15.2.3   | Sodium hypochlorite              | Solution                          | 4-6% chlorine                     | 1     |
| <b>16. DIURETICS</b>                               |                                  |                                   |                                   |       |
| 16.1   | AmilorideHCl                     | Tablet                            | 5mg                               | 4     |
| 16.2   | Furosemide                       | a) Injection                      | 10mg/mL (2mL amp)                 | 4     |
|  |                                  | b) Oral liquid [c]                | 20mg/5mL                          | 4     |
|  |                                  | c) Tablet (scored)                | 40mg                              | 4     |
| 16.3   | Hydrochlorthiazide               | Tablet(scored)                    | 25mg                              | 4     |
| 16.4   | Mannitol                         | Injection solution                | 20%                               | 4     |
| 16.5   | Spirolactone                     | Tablet                            | 25mg                              | 4     |
| <i>Specialist List [c]</i>                         |                                  |                                   |                                   |       |
| 16.6   | Hydrochlorthiazide               | Tablet (scored)                   | 25mg                              |       |
| 16.7   | Spirolactone                     | Tablet                            | 25mg                              |       |
| 16.8   | Mannitol                         | Injection solution                | 20%                               |       |
| <b>17. GASTROINTESTINAL MEDICINES</b>              |                                  |                                   |                                   |       |
| <b>17.1 Antacids and other antiulcer medicines</b> |                                  |                                   |                                   |       |
| 17.1.1   | Lansoprazole [c]                 | Dispersible tablet                | 15mg                              | 4     |
| 17.1.2   | Omeprazole                       | a) Capsule                        | 20mg                              | 4     |
|  |                                  | b) PFI (as sod. salt)             | 40mg vial                         | 4     |
| <b>17.2 Antiemetics</b>                            |                                  |                                   |                                   |       |
| 17.2.1   | Dexamethasone                    | Injection                         | 4mg/1mL amp (as sodium phosphate) | 4     |
| 17.2.2   | Domperidone <sup>171</sup>       | a) Oral liquid                    | 5mg/5mL                           | 4     |
|  |                                  | b) Tablet                         | 10mg                              | 4     |
| 17.2.3   | MetoclopramideHCl <sup>172</sup> | a) Injection                      | 5mg/mL (2mL amp)                  | 4     |
|  |                                  | b) Tablet                         | 10mg                              | 2     |
| 17.2.4   | Ondansetron <sup>173</sup>       | a) Injection                      | 2mg/mL (base, as HCl) (2mL amp)   | 4     |
|  |                                  | b) Tablet (orally disintegrating) | 4mg (base equivalent)             | 4     |
| <i>Specialist List</i>                             |                                  |                                   |                                   |       |
| 17.2.5   | Dexamethasone                    | Tablet                            | 500 micrograms                    |       |

<sup>170</sup> Previously called glutaraldehyde

<sup>171</sup> Alternative in patients who cannot tolerate metoclopramide and in young children requiring an oral liquid antiemetic; additional restrictions apply (small increased cardiac toxicity risk)

<sup>172</sup> Do not use in neonates

<sup>173</sup> Use only in patients >1 month

| #   | Drug   | Dose-form                        | Size/strength  | Level |
|---|--|----------------------------------|--|-------|
| <b>17.3 Anti-inflammatories</b>                                   |  |                                  |  |       |
| <i>Specialist List</i>  |  |                                  |  |       |
| 17.3.1  | Mesalazine                                       | Tablet (e/c)                     | 400mg  |       |
| 17.3.2  | Prednisolone                                     | Tablet                           | 5mg  |       |
| <b>17.4 Laxative</b>  |  |                                  |  |       |
| 17.4.1  | Bisacodyl  | a) Tablet                        | 5mg  | 2     |
|   |  | b) Suppository                   | 10mg   | 4     |
| <b>17.5 Medicines used in diarrhoea</b>                           |  |                                  |  |       |
| 17.5.1  | Oral rehydration solution (ORS)                  | PFOL (sachet for 500mL)          | WHO low-osmolality formula                           | 1     |
| 17.5.2  | ORS + zinc sulphate                              | Co-pack (4 sachets + 10 tablets) | 500mL sachets + zinc sulphate tab 20mg (dispersible) | 2     |
| 17.5.3  | Rehydration solution for malnutrition (ReSoMal)  | PFOL (sachet for 1L)             | WHO formula  | 4     |
| 17.5.4  | Zinc sulphate <sup>174</sup> [c]                 | Tablet (dispersible)             | 20mg   | 2     |
| <b>18. HORMONES, other ENDOCRINE MEDICINES and CONTRACEPTIVES</b> |  |                                  |  |       |
| <b>18.1 Adrenal hormones and synthetic substitutes</b>            |  |                                  |  |       |
| <i>Specialist List</i>  |  |                                  |  |       |
| 18.1.1  | Fludrocortisone acetate                          | Tablet                           | 100 micrograms                                       |       |
| <b>18.2 Androgens</b>   |  |                                  |  |       |
| None selected   |  |                                  |  |       |
| <b>18.3 Contraceptives</b>  |  |                                  |  |       |
| <b>18.3.1 Oral hormonal contraceptives</b>                        |  |                                  |  |       |
| 18.3.1.1  | Ethinylestradiol + levonorgestrel                | Tablet                           | 30 micrograms + 150 micrograms                       | 2     |
| 18.3.1.2  | Levonorgestrel                                   | Tablet                           | 30 micrograms  | 2     |
| <b>For emergency contraception</b>                                |  |                                  |  |       |
| 18.3.1.3  | Levonorgestrel                                   | Tablet                           | 750 micrograms (pack of 2)                           | 2     |
| <b>18.3.2 Injectable hormonal contraceptives</b>                  |  |                                  |  |       |
| 18.3.2.1  | Estradiolcypionate + medroxyprogesterone acetate | Injection                        | 5mg + 25mg   | 2     |
| 18.3.2.2  | Medroxyprogesterone acetate (DMPA)               | a) Depot injection (IM)          | 150mg/1mL (prefilled syringe)                        | 2     |
|   |  | b) Depot                         | 104mg/0.65ml   | 2     |

<sup>174</sup> Use with ORS in acute diarrhoea

| #  | Drug  | Dose-form                                   | Size/strength         | Level |
|--|---|---|-----------------------|-------|
|  |   | injection (SC) <sup>175</sup>               | (prefilled syringe)   |       |
| <b>18.3.3 Intrauterine devices (IUD)</b>     |   |   |                       |       |
| 18.3.3.1                                     | Copper-containing device <sup>176</sup>             |   |                       | 2     |
| 18.3.3.2                                     | Levonorgestrel (LNG)                                | LNG-releasing Intrauterine system (LNG-IUS) | Reservoir with 52mg   | 2     |
| <b>18.3.4 Barrier methods</b>                |   |   |                       |       |
| 18.3.4.1                                     | Male condom   |   |                       | 1     |
| 18.3.4.2                                     | Female condom                                       |   |                       | 1     |
| <b>18.3.5 Contraceptive implants</b>         |   |   |                       |       |
| 18.3.5.1                                     | Etonorgestrel-releasing                             | Implant                                     | 68mg (1 rod)          | 4     |
| 18.3.5.2                                     | Levonorgestrel-releasing                            | Implant                                     | 150mg (2 x 75mg rods) | 4     |
| <b>18.3.6 Intravaginal contraceptive</b>     |   |   |                       |       |
| 18.3.6.1                                     | Progesterone-releasing <sup>177</sup>               | Vaginal ring                                | 2.074g (micronized)   | 4     |
| <b>18.4 Estrogens</b>                        |   |   |                       |       |
| None selected                                |   |   |                       |       |
| <b>18.5 Insulins and other antidiabetics</b> |   |   |                       |       |
| 18.5.1                                       | Glibenclamide <sup>178</sup>                        | Tablet                                      | 5mg                   | 4     |
| 18.5.2                                       | Gliclazide <sup>179</sup>                           | Tablet                                      | 40mg                  | 4     |
| 18.5.3                                       | Insulin, soluble (human)                            | Injection                                   | 100 IU/mL (10mL vial) | 4     |
| 18.5.4                                       | Insulin, intermediate-acting (human) <sup>180</sup> | Injection                                   | 100 IU/mL (10mL vial) | 4     |
| 18.5.5                                       | MetforminHCl  | Tablet                                      | 500mg                 | 4     |
| <i>Specialist List [c]</i>                   |   |   |                       |       |
| 18.5.6                                       | Metformin HCl                                       | Tablet                                      | 500mg                 |       |
| <b>18.6 Ovulation inducer</b>                |   |   |                       |       |
| <i>Specialist List</i>                       |   |   |                       |       |
| 18.6.1                                       | Clomifene citrate                                   | Tablet                                      | 50mg                  |       |
| <b>18.7 Progestogens</b>                     |   |   |                       |       |
| <i>Specialist List</i>                       |   |   |                       |       |

<sup>175</sup> May be referred to as DMPA-SC

<sup>176</sup> Different registered preparations may be available

<sup>177</sup> For use in women actively breastfeeding at least 4 times daily

<sup>178</sup> Do not use for patients >60 years

<sup>179</sup> Use only in patients >60 years

<sup>180</sup> As biphasic isophane insulin (30% soluble insulin/70% isophane insulin)

| #   | Drug   | Dose-form                  | Size/strength   | Level       |
|---|--|----------------------------|---|-------------|
| 18.7.1  | Medroxyprogesterone acetate                                  | Tablet                     | 5mg   |             |
| <b>18.8 Thyroid hormones and anti-thyroid medicines</b> |  |                            |   |             |
| 18.8.1  | Carbimazole  | Tablet                     | 5mg   | 4           |
| 18.8.2  | Levothyroxine sodium   | Tablet                     | (a) 25 micrograms<br>[c]<br>(b) 50 micrograms<br>(c) 100 micrograms | 4<br>4<br>4 |
| <i>Specialist List</i>                                  |  |                            |   |             |
| 18.8.3  | Lugol's iodine [c]   | Oral liquid                | ~130mg total iodine/mL  |             |
| 18.8.4  | Propylthiouracil <sup>181</sup>                              | Tablet                     | 50mg  |             |
| <b>18.9 Other endocrine medicines</b>                   |  |                            |   |             |
| <i>Specialist List</i>                                  |  |                            |   |             |
| 18.9.1  | Bromocriptine <sup>182</sup>                                 | Tablet (scored)            | 2.5mg (as mesilate)   |             |
| <b>19. IMMUNOLOGICALS</b>                               |  |                            |   |             |
| <b>19.1 Diagnostic agents</b>                           |  |                            |   |             |
| 19.1.1  | Tuberculin, purified protein derivative (PPD) <sup>183</sup> | Injection (solution)       | 0.1mL vial (single dose) <sup>184</sup>                             | 4           |
| <b>19.2 Sera and immunoglobulins</b>                    |  |                            |   |             |
| 19.2.1  | Snake antivenom immunoglobulin                               | PFI + diluent (for IV use) | 10mL vial <sup>185</sup>  | 2           |
| <b>19.3 Vaccines</b>                                    |  |                            |   |             |
| <i>Recommended for all</i>                              |  |                            |   |             |
| 19.3.1  | BCG vaccine (live attenuated)                                | PFI + diluent              | 1mL vial (10 doses) <sup>186</sup>                                  | 2           |
| 19.3.2  | DPT + HiB + HepB vaccine (pentavalent)                       | Injection (suspension)     | 5mL vial (10 doses)   | 2           |
| 19.3.3  | HPV vaccine <sup>187</sup> (2-valent)                        | Injection (suspension)     | 1mL vial (2 doses)  | 2           |
| 19.3.4  | Measles vaccine (live attenuated)                            | PFI + diluent              | 5mL vial (10 doses)   | 2           |
| 19.3.5  | Polio vaccine (IPV)  | Injection                  | 5mL vial (10 doses)   | 2           |

<sup>181</sup>Use as drug of choice (ie. rather than carbimazole) during 1<sup>st</sup> trimester of pregnancy and in lowest effective dose to control hyperthyroid state

<sup>182</sup> Use for prevention or suppression of lactation

<sup>183</sup> For Mantoux test

<sup>184</sup> 2TU/0.1mL

<sup>185</sup> 11 species mixture covering *Bitis*, *Naja*, *Echis*, *Dendroaspis* spp

<sup>186</sup> Dose: adults 0.1mL, child <1 year 0.05mL

<sup>187</sup> Human papillomavirus vaccine; for school health programme roll-out

| #   | Drug  | Dose-form                         | Size/strength                              | Level |
|---|---|-----------------------------------|--|-------|
| 19.3.6  | Polio vaccine, oral (OPV)<br>(live attenuated)                                | Oral drops                        | 2mL vial (20 doses)                        | 2     |
| 19.3.7  | Rotavirus vaccine   | Oral suspension                   | 1.5mL (single dose)                        | 2     |
| 19.3.8  | Tetanus toxoid (adsorbed)   | Injection<br>(suspension)         | 20mL vial (10<br>doses) <sup>188</sup>     | 2     |
| Recommended for certain regions                       |   |                                   |  |       |
| 19.3.9  | Yellow fever vaccine <sup>189</sup>   | PFI + diluent                     | 10mL vial (20<br>doses) <sup>190</sup>     | 2     |
| Recommended for certain high-risk populations         |   |                                   |  |       |
| 19.3.10   | Cholera vaccine <sup>191</sup>  | Oral suspension                   | 1.5mL vial (single<br>dose)                | 2     |
| 19.3.11   | Hepatitis B vaccine (adult) <sup>192</sup>                                    | Injection<br>(suspension)         | 1mL vial (single<br>dose)                  | 4     |
| 19.3.12   | Meningococcal meningitis<br>vaccine <sup>193</sup>                            | PFI + diluent                     | 0.5mL vial<br>(single dose)                | 2     |
| 19.3.13   | Pneumococcal vaccine<br>(10-valent ads. conjugate)                            | Injection<br>(suspension)         | 1mL vial (2 doses)                         | 2     |
| 19.3.14   | Rabies vaccine <sup>194</sup><br>(cell culture)                               | PFI + diluent                     | 0.5mL vial<br>(single dose) <sup>195</sup> | 2     |
| 19.3.15   | Typhoid vaccine <sup>196</sup>  | Injection<br>(solution)           | 0.5mL vial<br>(single dose)                | 2     |
| 19.3.16   | Varicella vaccine <sup>197</sup>  | PFI + diluent                     | 0.5mL vial<br>(single dose)                | 4     |
| <i>Specialist List</i>                                |   |                                   |  |       |
| 19.3.17   | <i>Pneumococcal vaccine<br/>(23-valent adsorbed conjugate)</i> <sup>198</sup> | <i>Injection<br/>(suspension)</i> | <i>0.5mL vial (single dose)</i>            |       |
| <b>20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) and</b> |   |                                   |  |       |

<sup>188</sup> >40 IU/0.5mL dose

<sup>189</sup> Use only for health-workers during outbreaks & travellers to areas with yellow fever

<sup>190</sup> Contains 1,000 LD50 units/0.5mL dose

<sup>191</sup> Use only in management of outbreaks

<sup>192</sup> Use mainly for health providers and their dependants; contains 20 micrograms antigen protein/1mL dose

<sup>193</sup> Sero-type specific; use for outbreaks, asplenic patients & travellers to affected areas

<sup>194</sup> Human diploid type may also be available & used as a more expensive alternative

<sup>195</sup> Rabies antigen  $\geq 2.5$  IU/0.5 mL dose when reconstituted as a suspension

<sup>196</sup> Use reserved for specific at risk patients, ie. nephrotics, immunosuppressed patients, travellers to typhoid prevalent areas

<sup>197</sup> Also called chickenpox vaccine

<sup>198</sup> Use for patients with sickle-cell disease



| #   | Drug  | Dose-form                                   | Size/strength                     | Level |
|---|---|---|-----------------------------------|-------|
| <b>CHOLINESTERASE INHIBITORS</b>                |   |   |                                   |       |
| 20.1  | Atracuriumbesilate  | Injection                                   | 10mg/mL (5mL amp)                 | 4     |
| 20.2  | Cisatracurium   | Injection<br>(as besilate)                  | 2mg/mL (10mL vial)                | 4     |
| 20.3  | Glycopyrronium bromide +<br>neostigmine metilsulfate <sup>199</sup> | Injection                                   | 500 micrograms +<br>2.5mg/1mL amp | 4     |
| 20.4  | Neostigminemetilsulfate   | Injection                                   | 2.5mg/1mL amp                     | 4     |
| 20.5  | Pancuronium bromide   | Injection                                   | 2mg/mL (2mL amp)                  | 4     |
| 20.6  | Suxamethonium chloride  | Injection                                   | 50mg/mL (2mL amp)                 | 4     |
| <b>21. OPHTHALMOLOGICALS</b>                    |   |   |                                   |       |
| <b>21.1 Anti-infectives</b>                     |   |   |                                   |       |
| 21.1.1  | Gentamicin  | Eye drops                                   | 0.3% (as sulfate)                 | 2     |
| 21.1.2  | TetracyclineHCl   | Eye ointment                                | 1%                                | 1     |
| <i>Specialist List</i>                          |   |   |                                   |       |
| 21.1.3  | Aciclovir   | Eye ointment                                | 3%                                |       |
| 21.1.4  | Azithromycindihydrate   | Eye drops                                   | 1.5%                              |       |
| 21.1.5  | Ciprofloxacin   | Eye drops                                   | 0.3% (as HCl)                     |       |
| 21.1.6  | Econazole   | Eye drops                                   | 1%                                |       |
| <b>21.2 Anti-inflammatories</b>                 |   |   |                                   |       |
| 21.2.1  | Prednisolone  | a) Eye drops                                | 0.5% (sod.<br>phosphate)          | 4     |
|   |   | b) Tablet                                   | 5mg                               | 4     |
| <i>Specialist List</i>                          |   |   |                                   |       |
| 21.2.2  | Prednisolone  | Eye drops                                   | 1% (acetate)                      |       |
| 21.2.3  | Ketorolac trometamol  | Eye drops                                   | 0.5%                              |       |
| 21.2.4  | Methylprednisolone  | PFI   | 1g vial (as sodium succinate)     |       |
| 21.2.5  | Triamcinoloneacetone  | Injection <sup>200</sup><br>(aq.suspension) | 40mg/1mL amp                      |       |
| <b>21.3 Local anaesthetic</b>                   |   |   |                                   |       |
| 21.3.1  | TetracaineHCl <sup>201</sup>  | Eye drops                                   | 0.5%                              | 4     |
| <b>21.4 Miotics and anti-glaucoma medicines</b> |   |   |                                   |       |
| 21.4.1  | Acetazolamide   | Tablet                                      | 250mg                             | 4     |
| 21.4.2  | Timolol   | Eye drops                                   | 0.5% (as hyd.<br>maleate)         | 4     |
| <i>Specialist List</i>                          |   |   |                                   |       |
| 21.4.3  | Dorzolamide   | Eye drops                                   | 2% (as HCl)                       | 4     |

<sup>199</sup> Use only for reversal of neuromuscular blockade

<sup>200</sup> Use as a depot

<sup>201</sup> Previously called amethocaine; do not use in pre-term neonates

| #  | Drug  | Dose-form                        | Size/strength                             | Level |
|--|---|----------------------------------|---|-------|
| 21.4.4   | Latanoprost   | Eye drops                        | 0.005% <sup>202</sup>                     | 4     |
| <b>21.5 Cycloplegics and mydriatics</b>                    |   |                                  |   |       |
| 21.5.1   | Atropinesulfate <sup>203</sup>                              | Eye drops                        | 0.5%                                      | 4     |
| 21.5.2   | Tropicamide   | Eye drops                        | 0.5%                                      | 4     |
| <b>21.6 Anti-allergics</b>                                 |   |                                  |   |       |
| 21.6.1   | Sodium cromoglicate   | Eye drops                        | 2%  | 4     |
| <b>21.7 Anti-vascular endothelial growth factor (VEGF)</b> |   |                                  |   |       |
| <i>Specialist List</i>                                     |   |                                  |   |       |
| 21.7.1   | Bevacizumab   | Injection                        | 25mg/mL (4mL vial)                        |       |
| <b>22. OXYTOCICS and ANTIOXYTOCICS</b>                     |   |                                  |   |       |
| <b>22.1 Oxytocics</b>                                      |   |                                  |   |       |
| 22.1.1   | Dinoprostone<br>(Prostaglandin E <sub>2</sub> )             | Vaginal tablet                   | 3mg                                       | 4     |
| 22.1.2   | Ergometrine <sup>204</sup>                                  | Injection                        | 200 micrograms/1mL amp                    | 2     |
| 22.1.3   | Misoprostol <sup>205</sup>                                  | a) Tablet                        | 200 micrograms                            | 4     |
|  |   | b) Vaginal tablet <sup>206</sup> | 25 micrograms                             | 4     |
| 22.1.4   | Oxytocin  | Injection                        | 10 IU/1mL amp                             | 2     |
| <i>Specialist List</i>                                     |   |                                  |   |       |
| 22.1.5   | Mifepristone + misoprostol <sup>207</sup>                   | Tablet                           | 200mg +<br>200 micrograms                 | 4     |
| <b>22.2 Anti-oxytocics (tocolytics)</b>                    |   |                                  |   |       |
| 22.2.1   | Nifedipine  | Capsule                          | 10mg (immediate-release)                  | 4     |
| <b>23. DIALYSIS SOLUTIONS</b>                              |   |                                  |   |       |
| <i>Specialist List</i>                                     |   |                                  |   |       |
| 23.1.1   | Intraperitoneal dialysis solutions<br>(CAPD) <sup>208</sup> | Parenteral solutions             | Of appropriate composition <sup>209</sup> |       |
| 23.2.2   | Haemodialysis solutions                                     |                                  |   |       |

<sup>202</sup> 50 micrograms/mL

<sup>203</sup> Only use in patients >3 months

<sup>204</sup> As hydrogen maleate; ensure protection from light (amber ampoules, dark storage)

<sup>205</sup> Use with caution due to narrow safety margin

<sup>206</sup> Use only for induction of labour

<sup>207</sup> Use only under close supervision

<sup>208</sup> Continuous ambulatory peritoneal dialysis (fluid)

<sup>209</sup> Various dialysis solutions & systems are available & in use; selection of the most appropriate presentations will be made by specialists

| #   | Drug                             | Dose-form                  | Size/strength        | Level  |
|---|----------------------------------|----------------------------|----------------------|--------|
| <b>24. MEDICINES for MENTAL and BEHAVIOURAL DISORDERS</b> |                                  |                            |                      |        |
| <b>24.1 Antipsychotics</b>                                |                                  |                            |                      |        |
| 24.1.1  | ChlorpromazineHCl                | Injection                  | a) 25mg/mL (2mL amp) | 2      |
|   |                                  | Tablet                     | b) 50mg<br>c) 100mg  | 4<br>4 |
| 24.1.2  | Flupentixoldecanoate             | Injection (oily, depot)    | 20mg/mL (2mL amp)    | 4      |
| 24.1.3  | Fluphenazinedecanoate            | Injection (oily, depot)    | 25mg/1mL amp         | 4      |
| 24.1.4  | Haloperidol                      | Injection                  | a) 5mg/1mL amp       | 4      |
|   |                                  | Oral liquid <sup>210</sup> | b) 2mg/mL            | 4      |
|   |                                  | Tablet (scored)            | b) 5mg               | 4      |
| 24.1.5  | Olanzapine                       | Tablet (scored)            | 10mg                 | 4      |
| 24.1.6  | Zuclopenthixol acetate           | Injection (oily)           | 50mg/mL (2mL amp)    | 4      |
| <b>Specialist List</b>                                    |                                  |                            |                      |        |
| 24.1.7  | ChlorpromazineHCl [c]            | Injection                  | 25mg/mL (2mL amp)    |        |
| 24.1.8  | Clozapine                        | Tablet (scored)            | a) 25mg              |        |
|   |                                  |                            | b) 100mg             |        |
| 24.1.9  | Haloperidol [c]                  | a) Injection               | 5mg/1mL amp          |        |
|   |                                  | b) Tablet (scored)         | 5mg                  |        |
| 24.1.10   | Risperidone <sup>211</sup>       | Tablet                     | a) 500 micrograms    |        |
|   |                                  |                            | b) 2mg               |        |
| <b>24.2 Medicines used in mood disorders</b>              |                                  |                            |                      |        |
| <b>24.2.1 Medicines use in depressive disorders</b>       |                                  |                            |                      |        |
| 24.2.1.1  | AmitriptylineHCl                 | Tablet                     | 25mg                 | 4      |
| 24.2.1.2  | Fluoxetine                       | Tablet (scored)            | 20mg (as HCl)        | 4      |
| <b>Specialist List</b>                                    |                                  |                            |                      |        |
| 24.2.1.3  | Fluoxetine <sup>212</sup> [c]    | Tablet (scored)            | 20mg (as HCl)        |        |
| 24.2.1.4  | Mirtazapine <sup>213</sup>       | Tablet                     | a) 15mg              |        |
|   |                                  |                            | b) 30mg              |        |
| <b>24.2.2 Medicines used in bipolar disorders</b>         |                                  |                            |                      |        |
| 24.2.2.1  | Carbamazepine                    | Tablet (scored)            | 200mg                | 4      |
| 24.2.2.2  | Valproic acid (sodium valproate) | Tablet (enteric-coated)    | a) 200mg             | 4      |
|   |                                  |                            | b) 500mg             | 4      |

<sup>210</sup> Drops with dosing pipette

<sup>211</sup> Use only in adults

<sup>212</sup> Only use in patients >8 years

<sup>213</sup> Not recommended for use in patients <18 years (unfavourable risk/benefit)

| #   | Drug                                     | Dose-form               | Size/strength                           | Level |
|---|--|-------------------------|---|-------|
| <b>Specialist List</b>  |  |                         |   |       |
| 24.2.2.2  | Lithium carbonate                        | Tablet                  | 400mg (modified release)                |       |
| <b>24.3 Medicines used in anxiety disorders</b>                                     |  |                         |   |       |
| 24.3.1  | Bromazepam <sup>214</sup>                | Tablet (scored)         | 3mg                                     | 4     |
| <b>24.4 Medicines used in obsessive compulsive disorders</b>                        |  |                         |   |       |
| 24.4.1  | ClomipramineHCl                          | Capsule                 | 25mg                                    | 4     |
| <b>24.5 Medicine used in disorders due to psychoactive substance abuse</b>          |  |                         |   |       |
| 24.5.1  | Diazepam <sup>215</sup>                  | Tablet                  | 5mg                                     | 4     |
| 24.5.2  | Nicotine <sup>216</sup>                  | Chewing gum             | a) 2mg                                  | 4     |
|   |  |                         | b) 4mg                                  | 4     |
| <b>Specialist List<sup>217</sup></b>  |  |                         |   |       |
| 24.5.3  | B vitamins, high potency                 | a) Injection IM         | 7mL (in 2 amps) <sup>218</sup>          |       |
|   |  | b) Injection IV         | 10mL (2 x 5mL amps) <sup>219</sup>      |       |
| 24.5.4  | Buprenorphine + naloxone (both as HCl)   | Tablet (sublingual)     | a) 2mg + 500 micrograms<br>b) 8mg + 2mg |       |
| 24.5.5  | MethadoneHCl                             | Oral liquid             | 5mg/mL (concentrate)                    |       |
| 24.5.6  | NaltrexoneHCl                            | Tablet                  | 50mg                                    |       |
| <b>24.6 Medicine used in attention deficit hyperactivity disorder (ADHD)</b>        |  |                         |   |       |
| 24.6.1  | Methylphenidate <sup>220</sup>           | Tablet                  | 10mg                                    | 4     |
| <b>25. MEDICINES for RESPIRATORY DISORDERS</b>                                      |  |                         |   |       |
| <b>25.1 Anti-asthmatics and medicines for chronic obstructive pulmonary disease</b> |  |                         |   |       |
| 25.1.1  | Beclometasonedipropionate <sup>221</sup> | Inhalation (aerosol)    | 100 micrograms/ metered dose            | 2     |
| 25.1.2  | Epinephrine (adrenaline)                 | Injection               | 1mg/1mL amp <sup>222</sup>              | 2     |
| 25.1.3  | Salbutamol (as sulphate)                 | a) Inhalation (aerosol) | 100 micrograms/ metered dose            | 2     |
|   |  | b) Injection            | 50 micrograms/mL (5mL amp)              | 2     |

<sup>214</sup> Only use in anxiety with agitation

<sup>215</sup> Only use in management of alcohol dependence

<sup>216</sup> As polacrillex (polacrillin complex)

<sup>217</sup> Use under close supervision within substance dependency treatment programmes

<sup>218</sup> Ascorbic acid 500 mg, nicotinamide 160 mg, pyridoxine hydrochloride 50 mg, riboflavin 4 mg, thiamine hydrochloride 250mg/7mL

<sup>219</sup> Ascorbic acid 500 mg, nicotinamide 160 mg, pyridoxine hydrochloride 50 mg, riboflavin 4 mg, thiamine hydrochloride 250mg/10mL

<sup>220</sup> Use should be strictly controlled and actively monitored

<sup>221</sup> Budesonide inhalation 100 micrograms/metered dose is an available alternative

<sup>222</sup> As hydrochloride or hydrogen tartrate; strength also expressed as 0.1% or 1 in 1,000

| #   | Drug  | Dose-form                               | Size/strength   | Level |
|---|---|---|---|-------|
|   |   | c) Nebuliser solution                   | 5mg/mL  | 2     |
| <b>Specialist List</b>  |   |   |   |       |
| 25.1.5  | Formoterol fumarate + budesonide                | Dry powder inhaler                      | 6 micrograms + 200 micrograms/metered dose                  |       |
| 25.1.6  | Ipratropium bromide                             | a) Inhalation (aerosol)                 | 20 micrograms/metered dose                                  |       |
|   |   | b) Nebuliser solution                   | 250 micrograms/1mL unit dose vial (isotonic)                |       |
| 25.1.7  | Montelukast (as sodium salt)                    | a) Granules                             | 4mg sachet  |       |
|   |   | b) Tablet                               | 10mg  |       |
| <b>26. SOLUTIONS CORRECTING WATER, ELECTROLYTE and ACID-BASE DISTURBANCES</b> |   |   |   |       |
| <b>26.1 Oral</b>  |   |   |   |       |
| 26.1.1  | Oral rehydration solution (ORS)                 | PFOL (to make 500mL)                    | Sachet (WHO low-osmolality formula)                         | 1     |
| 26.1.2  | ORS + zinc sulphate                             | Co-pack                                 | 500mL sachets (4) + zinc sulphate tablets (disp.) 20mg (10) | 1     |
| 26.1.3  | Rehydration solution for malnutrition (ReSoMal) | PFOL (to make 1L)                       | Sachet (42g) (WHO formula)                                  | 3     |
| <b>26.2 Parenteral</b>  |   |   |   |       |
| 26.2.1  | Glucose   | Injectable solution                     | a) 5% (isotonic) (500mL infusion pack)                      | 2     |
|   |   |   | b) 10% (hypertonic) (500mL infusion pack)                   | 2     |
|   |   |   | c) 50% (hypertonic) (50mL amp) <sup>223</sup>               | 4     |
| 26.2.2  | Potassium chloride                              | a) Injectable solution                  | 11.2% (20mL amp) <sup>224</sup>                             | 4     |
|   |   | b) Injectable solution for dilution [c] | 15% (10mL amp) <sup>225</sup>                               | 4     |
| 26.2.3  | Sodium chloride                                 | Injectable solution                     | 0.9% (isotonic) (500mL) <sup>226</sup>                      | 2     |

<sup>223</sup> Use only in dialysis, ICU and other central line fluids enhancement

<sup>224</sup>Equivalent to K<sup>+</sup> and Cl<sup>-</sup> 1.5 mmol/mL

<sup>225</sup>Equivalent to K<sup>+</sup> and Cl<sup>-</sup> 2 mmol/mL

| #                                 | Drug  | Dose-form                         | Size/strength                            | Level  |
|-----------------------------------|---|-----------------------------------|--|--------|
| 26.2.4                            | Sodium hydrogen carbonate (bicarbonate)             | (infusion)<br>Injectable solution | 8.4% (10mL amp) <sup>227</sup>           | 2      |
| 26.2.5                            | Sodium lactate compound <sup>228</sup>              | Injectable solution (infusion)    | BP formula <sup>229</sup> (500 mL)       | 2      |
| <b>Specialist List [c]</b>        |   |                                   |  |        |
| 26.2.6                            | Sodium chloride                                     | Injectable solution               | 3%(hypertonic) <sup>230</sup> (10mL amp) |        |
| <b>26.3 Other</b>                 |   |                                   |  |        |
| 26.3.1                            | Water for injection                                 | Injection                         | 10mL amp                                 | 2      |
| <b>27. VITAMINS and MINERALS</b>  |   |                                   |  |        |
| 27.1                              | Calcium carbonate                                   | Tablet (chewable)                 | 1.25g <sup>231</sup>                     | 4      |
| 27.2                              | Calcium gluconate                                   | Injection                         | 100mg/mL (10%) (10 mL amp)               | 4      |
| 27.3                              | Cholecalciferol (Vit D <sub>3</sub> )               | Oral liq. (drops) [c]             | 400 IU/mL <sup>232</sup>                 | 4      |
| 27.4                              | Ergocalciferol (Vit D <sub>2</sub> )                | Tablet                            | 1.25mg (50,000 IU)                       | 4      |
| 27.5                              | PyridoxineHCl (Vit B <sub>6</sub> ) <sup>233</sup>  | Tablet (scored)                   | 50mg                                     | 4      |
| 27.6                              | Retinol (Vit A) (as palmitate)                      | Capsule                           | a) 100,000 IU<br>b) 200,000 IU           | 2<br>2 |
| 27.7                              | ThiamineHCl (Vit B <sub>1</sub> ) <sup>234</sup>    | Tablet                            | 50mg                                     | 4      |
| <b>Specialist List [c]</b>        |   |                                   |  |        |
| 27.8                              | Ergocalciferol (Vit D <sub>2</sub> ) <sup>235</sup> | Injection IM (oily)               | 300,000 IU/1mL amp <sup>236</sup>        |        |
| <b>28. EAR and NOSE MEDICINES</b> |   |                                   |  |        |
| <b>28.1 Ear medicines</b>         |   |                                   |  |        |
| 28.1.1                            | CiprofloxacinHCl                                    | Solution                          | 0.3%                                     | 2      |

<sup>226</sup> Equivalent to Na<sup>+</sup> and Cl<sup>-</sup> 154 mmol/L

<sup>227</sup> Equivalent to Na<sup>+</sup> and HCO<sub>3</sub><sup>-</sup> 1,000 mmol/L

<sup>228</sup> Ringer's lactate, Hartmann's solution

<sup>229</sup> Equivalent to Na<sup>+</sup> 131, K<sup>+</sup> 5, Ca<sup>2+</sup> 2, Cl<sup>-</sup> 111, HCO<sub>3</sub><sup>-</sup> (as lactate) 29 mmol/L

<sup>230</sup> Equivalent to Na<sup>+</sup> and Cl<sup>-</sup> 513 mmol/L; use in bronchiolitis, and in hyponatremia in renal conditions in children

<sup>231</sup> Equivalent to calcium (elemental) 500mg (Ca<sup>2+</sup> 12.5mmol)

<sup>232</sup> Equivalent to 10 micrograms/mL

<sup>233</sup> Only use in TB patients for isoniazid-induced neuropathy

<sup>234</sup> Only use in alcohol withdrawal and properly diagnosed vitamin B deficiency

<sup>235</sup> Use only where oral therapy not tolerated or adherence likely to be poor

<sup>236</sup> Equivalent to 7.5mg

| #   | Drug  | Dose-form  | Size/strength                                       | Level |
|---|---|--|---|-------|
| 28.1.2  | Hydrogen peroxide <sup>237</sup>              | (ear drops)<br>Solution<br>(ear drops)           | 3%  | 3     |
| <b>Specialist List</b> <sup>238</sup>                 |   |  |   |       |
| 28.1.3  | Ciprofloxacin HCl +<br>betamethasone sodium   | Solution (ear<br>drops)                          | 0.3% + 0.1%   |       |
| 28.1.4  | Clotrimazole                                  | Solution (ear<br>drops)                          | 1%  |       |
| <b>28.2 Nose medicines</b>                            |   |  |   |       |
| 28.2.1  | Liquid paraffin                               | Nasal drops                                      | 100%  | 2     |
| 28.2.2  | Sodium chloride                               | Solution<br>(nasal drops)                        | 0.9%  | 2     |
| <b>Specialist List</b> <sup>239</sup>                 |   |  |   |       |
| 28.2.3  | Budesonide                                    | Nasal spray                                      | 100 micrograms/metered<br>dose                      |       |
| <b>29. SPECIFIC MEDICINES for NEONATAL CARE</b>       |   |  |   |       |
| <b>29.1 Medicines administered to the neonate [c]</b> |   |  |   |       |
| 29.1.1  | Chlorhexidine gluconate <sup>240</sup>        | Gel  | 7.1% (10 mL bottle +<br>dropper)                    | 2     |
| <b>Specialist List</b>                                |   |  |   |       |
| 29.1.2  | Caffeine citrate                              | a) Injection<br>b) Oral liq. (drops)             | 20mg/mL <sup>241</sup> (3mL vial)<br>20mg/mL        |       |
| 29.1.3  | Ibuprofen                                     | Injection solution                               | 5mg/mL (2mL amp)                                    |       |
| 29.1.4  | Prostaglandin E <sub>1</sub><br>(alprostadil) | Injection solution                               | 500 micrograms/1 mL amp<br>(in alcohol)             |       |
| 29.1.5  | Surfactant                                    | Suspension for<br>intra-tracheal<br>instillation | 25mg/mL <sup>242</sup> or<br>80mg/mL <sup>243</sup> |       |
| <b>29.2 Medicines administered to the mother</b>      |   |  |   |       |
| 29.2.1  | Dexamethasone                                 | Injection  | 4mg/mL<br>(as sodium<br>phosphate)                  | 4     |

<sup>237</sup> This 3% strength is also expressed as '10-volume'. If the ear drops are unavailable, use other available forms & strengths and dilute as required to 3% for use as ear drops

<sup>238</sup> Specialists here include Clinical Officer specially trained in ENT

<sup>239</sup> Specialists here include Clinical Officer specially trained in ENT

<sup>240</sup> Use for umbilical cord care; delivering chlorhexidine 4%

<sup>241</sup> Equivalent to 10mg caffeine base/mL

<sup>242</sup> Beractant (bovine lung extract) (4mL single-use vial)

<sup>243</sup> Poractant alpha (porcine lung phospholipid fraction) (1.5mL vial)

| #  | Drug   | Dose-form                            | Size/strength  | Level |
|--|--|--------------------------------------|--|-------|
| <b>30. MEDICINES used in JOINT DISEASES</b>                                |  |                                      |  |       |
| <b>30.1 Medicine for gout</b>  |  |                                      |  |       |
| 30.1.1   | Allopurinol  | Tablet (scored)                      | 300mg  | 4     |
| <b>30.2 Disease-modifying agents used in rheumatoid disorders (DMARDs)</b> |  |                                      |  |       |
| 30.2.1   | Chloroquine  | Tablet                               | 150mg (phosphate or sulphate)  | 4     |
| <i>Specialist List</i>   |  |                                      |  |       |
| 30.2.2   | Azathioprine   | Tablet                               | 50mg   |       |
| 30.2.3   | Leflunomide <sup>244</sup>   | Tablet                               | 20mg   |       |
| 30.2.4   | Methotrexate   | Tablet                               | 2.5mg  |       |
| 30.2.5   | Sulfasalazine  | Tablet                               | 500mg  |       |
| <b>30.3 Juvenile joint disease</b>   |  |                                      |  |       |
| 30.3.1   | Aspirin <sup>245</sup>   | Tablet (scored)                      | 300mg  | 4     |
| <b>31. PREPARATIONS for PARENTERAL NUTRITION</b>                           |  |                                      |  |       |
| <i>Specialist List</i>   |  |                                      |  |       |
| 31.1   | Amino acids <sup>246</sup>   | Infusion                             | a) 5-6% with glucose [c] (100mL bottle)<br>b) 10% (with electrolytes) (500mL bottle) |       |
| 31.2   | Fat (lipid) <sup>247</sup>   | Infusion (emulsion)                  | a) 10% (500mL)<br>b) 20% (100mL [c] & 500mL)   |       |
| 31.3   | Total parenteral nutrition (TPN) (amino acids + lipids + glucose + electrolytes) | Infusion (emulsion) (triple-chamber) | Composition & size according to specialist requirements                              |       |
| <b>32. PREPARATIONS for MANAGING SEVERE ACUTE MALNUTRITION</b>             |  |                                      |  |       |
| <i>Specialist List</i>   |  |                                      |  |       |
| 32.1   | Ready to use therapeutic food (RUTF) <sup>248</sup>                              | Oral paste                           | Standard formula (500 kcal sachet)   |       |
| 32.2   | F-75 therapeutic milk <sup>249</sup>   | PFOL (for approx. 600mL)             | Standard formula (102.5g sachet)   |       |

<sup>244</sup> Use only when methotrexate and sulfasalazine cannot be used

<sup>245</sup> Use in treatment of acute or chronic rheumatic fever, juvenile arthritis, Kawasaki disease

<sup>246</sup> Required product/composition to be determined by the specialist

<sup>247</sup> Required product/presentation to be determined by the specialist

<sup>248</sup> Micronutrient-fortified peanut/milk paste providing 500 kcal per sachet

<sup>249</sup> Micronutrient-fortified milk powder for reconstitution with water; also known as Formula 75, or Phase 1 (stabilisation phase) Therapeutic Milk



| #   | Drug                                  | Dose-form | Size/strength                     | Level |
|---|---------------------------------------|-----------|-----------------------------------|-------|
| 32.3                                      | F-100 therapeutic milk <sup>250</sup> |           | Standard formula<br>(114g sachet) |       |
| <b>33. MEDICINES for other CONDITIONS</b> |                                       |           |                                   |       |
| <i>Specialist List</i>                    |                                       |           |                                   |       |
| 33.1                                      | Levamisole <sup>251</sup>             | Tablet    | 50mg (as HCl)                     |       |

---

<sup>250</sup> Micronutrient-fortified milk powder for reconstitution with water; also known as Formula 100, or Phase 2(rehabilitation phase) Therapeutic Milk

<sup>251</sup> Use in treatment of nephrotic syndrome

# Index

- Abacavir (ABC), 15, 27  
Abacavir + lamivudine, 4, 28  
Absolute alcohol, 22  
Acetazolamide, 46  
Acetic acid, 18  
Acetylcysteine, 21  
Aciclovir, 3, 27  
Aciclovir (eye), 10  
Aciclovir, eye, 46  
Activated charcoal, 2, 21  
Adrenaline, 7, 21, 37, 49  
Air, medical, 1  
Albendazole, 2, 23  
Alendronic acid, 31  
Allopurinol, 13, 14, 31, 52  
Alprostadil, 52  
Amethocaine, 46  
Amidotrizoate, 40  
Amikacin, 26  
Amiloride, 41  
Amino acids, 53  
Aminophylline, 14  
Amiodarone, 37  
Amitriptyline, 20, 48  
Amlodipine, 37  
Amoxicillin, 2, 15, 23  
Amoxicillin + clavulanic acid, 2, 15, 23  
Amphotericin B, 26, 29  
Ampicillin, 15  
Anastrozole, 6, 34  
Anti-D immunoglobulin, 36  
Anti-rabies immunoglobulin, 36  
Anti-tetanus immunoglobulin, 36  
Artemether, 16  
Artemether + lumefantrine, 4, 29  
Artesunate, 4, 29  
Ascorbic acid, 18  
Asparaginase, 31  
Aspirin, 13, 20, 30, 38, 53  
Atazanavir + ritonavir, 3, 27  
Atenolol, 17  
Atorvastatin, 8  
Atovaquone + proguanil, 4, 30  
Atracurium, 10, 45  
Atropine, 19, 22  
Atropine (eye), 11, 18  
Atropine, eye, 46  
Azathioprine, 31, 52  
Azithromycin, 24  
Azithromycin (eye), 10, 46  
B vitamins, 12, 49  
Barium sulphate, 40  
BCG vaccine, 44  
Beclometasone inhaler, 49  
Beclomethasone inhalation, 18  
Bedaquiline, 3, 26  
Benzathine benzylpenicillin, 23  
Benzathine penicillin, 2, 15  
Benzhexol, 35  
Benzoyl peroxide, 8, 39  
Benzyl benzoate, 39  
Benzylpenicillin, 15, 24  
Beractant, 52  
Betamethasone (topical), 39  
Bevacizumab, 11, 47  
Bicalutamide, 6, 34  
Biperiden, 17  
Biphasic isophane insulin, 43  
Bisacodyl, 9, 20, 42  
Bleomycin, 31  
Blood (whole), 7, 36  
Bromazepam, 11, 48  
Bromocriptine, 44  
Budesonide (nose), 13, 52  
Budesonide inhalation, 49  
Bupivacaine, 14, 19  
Buprenorphine + naloxone, 12, 49  
Caffeine citrate, 52  
Calamine, 17  
Calcium carbonate, 12, 51  
Calcium folinate, 31  
Calcium gluconate, 51

*Capecitabine*, 5, 32  
*Capreomycin*, 3, 26  
*Carbamazepine*, 18, 22, 48  
*Carbimazole*, 44  
*Carboplatin*, 5, 32  
*Carvedilol*, 7, 8, 37, 38  
*Cefazolin*, 2, 24  
*Cefixime*, 24  
*Ceftazidime*, 24  
*Ceftriaxone*, 24  
*Cefuroxime*, 15  
*Cetirizine*, 2, 21  
*Charcoal (activated)*, 2, 21  
*Chickenpox vaccine*, 45  
*Chlorambucil*, 32  
*Chloramphenicol*, 15  
*Chlorhexidine*, 8, 40, 52  
*Chloroquine*, 52  
*Chlorphenamine*, 1, 14, 19  
*Chlorpromazine*, 11, 47, 48  
*Cholecalciferol*, 12, 18, 51  
*Cholera vaccine*, 10, 45  
*Ciclosporin*, 31  
*Ciprofloxacin*, 3, 24, 25  
*Ciprofloxacin (ear)*, 51  
*Ciprofloxacin (eye)*, 10  
*Ciprofloxacin + betamethasone*, 13  
*Ciprofloxacin, eye*, 46  
*Cisatracurium*, 10, 46  
*Cisplatin*, 5, 32  
*Clarithromycin*, 24  
*Clindamycin*, 25  
*Clobetasone*, 8, 39  
*Clofazamine*, 3, 25  
*Clomifene*, 43  
*Clomipramine*, 12, 49  
*Clonidine*, 18  
*Clopidogrel*, 8, 38  
*Clotrimazole (ear)*, 13, 51  
*Clotrimazole (topical)*, 38  
*Clotrimazole (vaginal)*, 3, 15, 26  
*Clozapine*, 11, 48  
*Coagulation factor IX*, 37  
*Coagulation factor VIII*, 37  
*Coal tar*, 17  
*Coal tar + salicylic acid*, 8, 39  
*Co-amoxiclav*, 23  
*Codeine*, 20  
*Condom (female)*, 43  
*Condom (male)*, 43  
*Copper-containing device (IUD)*, 43  
*Cotrimoxazole*, 24, 30  
*Crisantaspase*, 31  
*Crotamiton*, 8, 39  
*cyanocobalamin*, 35  
*Cyclizine*, 14  
*Cyclophosphamide*, 5, 32  
*Cycloserine*, 3, 26  
*Cytarabine*, 32  
*Dacarbazine*, 5, 17, 32  
*Dactinomycin*, 32  
*Dapsone*, 16, 25  
*Darunavir*, 3, 27  
*Daunorubicin*, 32  
*Deferasirox*, 2, 7, 22, 36  
*Deferoxamine*, 7, 22, 36  
*Dehydrated alcohol*, 22  
*Delamanid*, 3, 26  
*Desonide*, 8, 39  
*Dexamethasone*, 6, 9, 13, 20, 21, 34, 41, 42, 52  
*Dextran 70*, 17  
*Diazepam*, 1, 2, 12, 14, 18, 20, 22, 49  
*Diclofenac*, 14  
*Didanosine*, 15  
*Diethylcarbamazine*, 2, 23  
*Diethylstilboestrol*, 34  
*Digoxin*, 37, 38  
*Dihydroartemisinin + piperaquine*, 16  
*Diloxanide*, 29  
*Dimercaprol*, 22  
*Dimercaptosuccinic acid*, 22  
*Dinoprostone*, 47  
*Dithranol*, 17  
*DMPA-SC*, 43  
*DMSA*, 22  
*Docetaxel*, 5, 32  
*Docusate*, 14

Domperidone, 9, 41  
 Dopamine, 38  
 Dorzolamide, 10, 46  
 Doxorubicin, 5, 32  
 Doxycycline, 16, 25, 30  
 DPT + HiB + HepB vaccine  
     (pentavalent), 44  
 Econazole, 10  
 Econazole (eye), 10, 46  
 Efavirenz, 3, 16  
 Efavirenz (EFV or EFZ), 27  
 Efavirenz + emtricitabine + tenofovir,  
     16  
 Efavirenz + lamivudine + tenofovir, 4,  
     28  
 Enalapril, 38  
 Enoxaparin, 7, 36  
 Epinephrine, 7, 21, 37, 49  
 Epinephrine (eye), 11  
 Ergocalciferol, 13, 18  
 Ergometrine, 47  
 Erythromycin, 15  
 Estradiol + medroxyprogesterone, 42  
 Estradiol cypionate +  
     medroxyprogesterone acetate, 9  
 Ethambutol, 15, 25  
 Ethanol, 2, 22, 40  
 Ethinylestradiol + levonorgestrel, 42  
 Ethinylestradiol + norethisterone, 17  
 Ethosuximide, 14  
 Etonorgestrel implant, 43  
 Etoposide, 17, 32  
 Etravirine (ETV), 27  
 Fat emulsion, 53  
 Female condom, 43  
 Fentanyl, 1, 20  
 Ferrous salt, 7, 35  
 Ferrous salt + folic acid, 35  
 Ferrous sulphate, 35  
 Filgrastim, 5, 33  
 Finasteride, 6, 35  
 Flucloxacillin, 24  
 Fluconazole, 26  
 Fludrocortisone, 42  
 Flumazenil, 2, 22  
 Fluorescein, 8, 40  
 Fluorouracil, 33  
 Fluoxetine, 11, 48  
 Flupentixol, 11, 48  
 Fluphenazine, 48  
 Folic acid, 7, 35  
 Fomepizole, 2, 22  
 Food (therapeutic), 13, 53  
 Formoterol + budesonide, 49  
 Formoterol fumarate + budesonide, 12  
 Furosemide, 8, 38, 41  
 Fusidic acid, 39  
 Gabapentin, 1, 2, 21, 22  
 Gadobutrol, 40  
 Gadodiamide, 40  
 Gadopentate dimeglumine, 40  
 Ganciclovir, 4, 28  
 Gelatin, 37  
 Gemcitabine, 5, 33  
 Gentamicin, 25, 46  
 Gentamicin, eye, 46  
 Glibenclamide, 43  
 Gliclazide, 9, 43  
 Glucose, 50  
 Glutaral, 41  
 Glutaraldehyde, 41  
 Glyceryl trinitrate, 37  
 Glycopyrronium bromide +  
     neostigmine metilsulfate, 10, 46  
 Goserelin, 6, 34  
 Griseofulvin, 27  
 Haemodialysis solutions, 11, 47  
 Haloperidol, 1, 11, 21, 48  
 Halothane, 19  
 Hand rub, 8, 41  
 Heparin, 36  
 Hepatitis B vaccine, 45  
 HPV vaccine, 44  
 Hydralazine, 38  
 Hydrochlorothiazide, 38, 41  
 Hydrocortisone, 17, 21  
 Hydrocortisone, topical, 39  
 Hydrogen peroxide (ear), 13, 51

Hydroxocobalamin, 35  
 Hydroxycarbamide, 5, 7, 33, 36  
 Hydroxycortisone, 34  
 Hydroxyurea, 5, 33, 36  
 Hyoscine butylbromide, 1, 21  
 Hyoscine hydrobromide, 14, 21  
 Ibuprofen, 20, 30, 52  
 Ifosfamide, 5, 33  
 Imatinib, 5, 33  
 Imipenem + cilastin, 3, 24  
 Immunoglobulin (anti-D), 36  
 Immunoglobulin (anti-rabies), 36  
 Immunoglobulin (anti-tetanus), 36  
 Immunoglobulin (normal), 7, 37  
 Immunoglobulin (snake antivenom),  
     44  
 Insulin (biphasic isophane), 43  
 Insulin (intermediate-acting), 43  
 Insulin (soluble), 43  
 Intraperitoneal dialysis solutions, 47  
 Iohexol, 40  
 Iopromide, 40  
 Ipratropium, 12, 49  
 Irinotecan, 5, 33  
 Isoflurane, 1, 19  
 Isoniazid, 15, 25  
 Isoniazid + ethambutol, 26  
 Isosorbide dinitrate, 37  
 Ivermectin, 8, 15, 39  
 Kanamycin, 26  
 Ketamine, 19  
 Ketorolac, 10, 46  
 Lactulose, 1, 21  
 Lamivudine (3TC), 27  
 Lamivudine + nevirapine + stavudine,  
     16  
 Lamivudine + nevirapine + zidovudine,  
     28  
 Lamivudine + stavudine, 16  
 Lamivudine + tenofovir, 4, 28  
 Lamivudine + zidovudine, 4, 28  
 Lamotrigine, 2, 23  
 Lansoprazole, 9, 41  
 Latanoprost, 11, 46  
 Leflunomide, 13, 52  
 Levamisole, 53  
 Levodopa + carbidopa, 6, 35  
 Levofloxacin, 3, 26  
 Levonorgestrel, 9, 42, 43  
 Levonorgestrel (implant), 43  
 Levothyroxine, 44  
 Lidocaine, 1, 19, 37  
 Lidocaine (topical), 1, 19  
 Lidocaine + epinephrine, 19  
 Lignocaine, 14  
 Lignocaine (dental), 14  
 Lignocaine (topical), 14  
 Lignocaine + adrenaline, 14  
 Linezolid, 3, 26  
 Liquid paraffin, 13, 52  
 Lithium, 11, 18, 48  
 Loperamide, 1, 21  
 Lopinavir + ritonavir, 16, 27  
 Lorazepam, 2, 22  
 Losartan, 8, 38  
 Lugol's iodine, 10, 44  
 Magnesium sulphate, 23  
 Magnesium trisilicate, 17  
 Male condom, 43  
 Mannitol, 17, 41  
 Measles vaccine, 44  
 Medical air, 1, 19  
 Medroxyprogesterone acetate, 9, 42,  
     43  
 Meglumine iotroxate, 40  
 Melarsoprol, 30  
 Melphalan, 5, 33  
 Meningococcal meningitis vaccine, 45  
 Mercaptopurine, 33  
 Mesalazine, 9, 42  
 Mesna, 5, 33  
 Metformin, 43  
 Methadone, 49  
 Methotrexate, 5, 33, 52  
 Methyl dopa, 38  
 Methylphenidate, 12, 49  
 Methylprednisolone, 4, 6, 10, 17, 31, 35,  
     46

Metoclopramide, 1, 21, 41  
 Metronidazole, 15, 25, 29  
 Midazolam, 1, 19, 21  
 Mifepristone + misoprostol, 47  
 Milk (therapeutic), 13, 53  
 Mirtazapine, 11, 48  
 Misoprostol, 47  
 Mometasone, 8, 39  
 Montelukast, 12, 50  
 Morphine, 1, 14, 19, 20  
 Moxifloxacin, 3, 26  
 Mupirocin, 39  
 Mycophenolic acid, 4, 31  
 Naloxone, 22  
 Naltrexone, 12, 49  
 Neostigmine, 46  
 Nevirapine (NVP), 27  
 Niclosamide, 15  
 Nicotinamide, 18  
 Nicotine, 12, 49  
 Nifedipine, 47  
 Nitrofurantoin, 25  
 Nitrous oxide, 19  
 Norethisterone enantate, 18  
 Normal immunoglobulin, 7, 37  
 Nystatin, 27  
 Ofloxacin, 15  
 Olanzapine, 11, 48  
 Omeprazole, 9, 41  
 Ondansetron, 2, 9, 21, 41  
 Oral rehydration solution, 9, 42, 50  
 ORS, 9  
 ORS + zinc sulphate, 12, 42, 50  
 Oxaliplatin, 6, 33  
 Oxygen, 19  
 Paclitaxel, 6, 34  
*p*-aminosalicylic acid, 3, 26  
 Pancuronium, 10, 46  
 Paracetamol, 1, 4, 14, 20, 30  
 Paraffin (liquid), 52  
 Paraffin (soft white), 39  
 Paromomycin, 29  
 PAS, 26  
 Pegylated interferon, 4, 28  
 Penicillamine, 22  
 Pentamidine, 30  
 Petroleum jelly, 39  
 Phenobarbital, 2, 23  
 Phenoxymethylpenicillin, 3, 24  
 Phenytoin, 23  
 Phytomenadione, 7, 17, 36  
 Pilocarpine, 18  
 Plasma (fresh frozen), 7, 36  
 Platelets, 7, 36  
 Pneumococcal vaccine, 10, 45  
 Podophyllum resin, 39  
 Polio vaccine (IPV), 10, 44  
 Polio vaccine oral (OPV), 44  
 Polygeline, 7, 37  
 Polyvidone iodine (mouthwash), 18  
 Poractant, 52  
 Potassium chloride, 12, 18, 50  
 Povidone iodine, 40  
 Pralidoxime, 2, 22  
 Pramipexole, 6, 35  
 Praziquantel, 23  
 Prednisolone, 5, 6, 9, 10, 14, 17, 21, 31, 35, 42  
 Prednisolone (eye), 10  
 Prednisolone, eye, 46  
 Procarbazine, 34  
 Progesterone (vaginal ring), 9, 43  
 Proguanil, 4, 30  
 Promethazine, 14, 17  
 Propofol, 1, 19  
 Propranolol, 30  
 Propylthiouracil, 10, 44  
 Prostaglandin E<sub>1</sub>, 52  
 Prostaglandin E<sub>2</sub>, 47  
 Protamine, 2, 22, 36  
 Prothionamide, 3, 26  
 Pyrazinamide, 26  
 Pyridoxine, 13, 18, 51  
 Pyrimethamine, 16  
 Quinine, 16  
 Rabies vaccine, 45  
 Raltegravir, 3, 27  
 Ranitidine, 17

Red blood cells, 7, 36  
 ReSoMal, 9, 12, 42, 50  
 Retinol, 51  
*Ribavirin*, 4, 28  
*Rifabutin*, 3, 26  
*Rifampicin*, 25, 26  
*Rifampicin* + *isoniazid*, 26  
*Rifampicin* + *isoniazid* + *ethambutol*, 26  
*Rifampicin* + *isoniazid* + *pyrazinamide*,  
 3, 26  
*Rifampicin* + *isoniazid* + *pyrazinamide* +  
*ethambutol*, 26  
*Risperidone*, 11, 48  
*Ritonavir*, 3, 27  
*Rituximab*, 6, 34  
 Rotavirus vaccine, 10, 45  
*RUTF*, 13  
*Salbutamol*, 18, 49  
 Salicylic acid, 17  
 Silver sulphadiazine, 39  
*simvastatin*, 38  
 Snake antivenom immunoglobulin, 44  
 Sodium bicarbonate, 18, 50  
*Sodium calcium edetate*, 22  
*Sodium chloride*, 12, 50  
 Sodium chloride, nose, 13, 52  
 Sodium cromoglicate, 47  
 Sodium cromoglicate (eye), 11  
 Sodium fusidate, 39  
 Sodium hydrogen carbonate, 18, 50  
 Sodium lactate compound, 50  
*Sodium nitrite*, 2, 22  
*Sodium nitroprusside*, 38  
*Sodium stibogluconate*, 29  
*Sodium thiosulphate*, 2, 22  
 Sodium valproate, 11, 23, 48  
 Soft paraffin (white), 39  
 Spironolactone, 8, 38, 41  
 Stavudine, 16  
 Streptokinase, 17  
*Succimer*, 22  
 Sulfadoxine + pyrimethamine, 4, 30  
 Sulfamethoxazole + trimethoprim, 24  
 Sulfasalazine, 17, 52  
 Sulphadiazine, 17  
 Sunscreening agent, 8, 39  
*Suramin*, 30  
 Surfactant, 52  
 Suxamethonium, 46  
*Tacrolimus*, 5, 8, 31, 39  
*Tamoxifen*, 6, 35  
*Tamsulosin*, 6, 35  
*Tenofovir*, 4, 16, 28  
 Terbinafine, 8, 38  
 Tetanus toxoid (adsorbed), 45  
 Tetanus vaccine, 45  
 Tetracaine, 46  
 Tetracycline, 46  
*Thalidomide*, 6, 34  
 Therapeutic food, 13, 53  
 Therapeutic milk, 13, 53  
 Thiamine, 51  
 Thiopental, 19  
 Timolol, 18, 46  
 Tinidazole, 3, 25, 29  
 Tranexamic acid, 7, 36  
*Trastuzumab*, 6, 34  
*Triamcinolone*, 10  
*Triamcinolone*, eye, 46  
 Tropicamide, 11, 40, 47  
 Tuberculin (purified protein  
 derivative), 44  
 Typhoid vaccine, 45  
 Vaccine, BCG, 44  
 Vaccine, chickenpox, 45  
 Vaccine, cholera, 10, 45  
 Vaccine, DPT+HiB+HepB (pentavalent),  
 44  
 Vaccine, hepatitis B, 45  
 Vaccine, HPV, 44  
 Vaccine, measles, 44  
 Vaccine, meningococcal meningitis, 45  
 Vaccine, oral polio (OPV), 44  
 Vaccine, pneumococcal, 10, 45  
 Vaccine, polio, 10  
 Vaccine, polio (IPV), 44  
 Vaccine, rabies, 45  
 Vaccine, rotavirus, 10, 45

Vaccine, tetanus, 45  
Vaccine, typhoid, 45  
Vaccine, varicella, 10, 45  
Vaccine, yellow fever, 45  
Valproic acid, 11, 23, 48  
Vancomycin, 25  
Varicella vaccine, 10, 45  
Vecuronium, 18  
Verapamil, 7, 17, 37  
Vinblastine, 6, 34  
Vincristine, 17  
Vinorelbine, 6, 34  
Vit D<sub>3</sub>, 12  
Vitamin A, 51  
Vitamin B<sub>1</sub>, 51  
Vitamin B<sub>3</sub>, 18  
Vitamin B<sub>6</sub>, 13, 18, 51  
Vitamin D<sub>2</sub>, 13, 51  
Vitamin D<sub>3</sub>, 12, 51  
Vitamin K<sub>1</sub>, 17, 36  
Vitamins B, 12, 49  
Warfarin, 7, 36  
Water for injection, 51  
White petrolatum, 39  
White soft paraffin, 8, 39  
Whole blood, 7, 36  
Yellow fever vaccine, 45  
Zidovudine, 16  
Zinc sulphate, 42  
Zoledronic acid, 6, 34  
Zuclopenthixol, 11, 48